UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number 001-36245
RiceBran Technologies
(Exact Name of Registrant as Specified in its Charter)

California
  
87-0673375
 (State or other jurisdiction of
incorporation or organization)
  
 (I.R.S. Employer Identification No.)

1330 Lake Robbins Drive, Suite 250
The Woodlands, TX
  
77380
(Address of Principal Executive Offices) 
  
 (Zip Code)

(281) 675-2421
(Registrant’s telephone number, including area code)
 
None
(Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock, no par value per share
 
RIBT
 
The NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
     
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule l2b-2 of the Exchange Act).  Yes ☐ No ☒

As of November 2, 2020, shares of the registrant’s common stock outstanding totaled 41,972,594.

RiceBran Technologies
Index
Form 10-Q

PART I. FINANCIAL INFORMATION
Page
 
Item 1.
3
 
   3
 
   4
    5
    6
    7
 
Item 2.
18
 
Item 3.
20
 
Item 4.
20
PART II. OTHER INFORMATION
 
Item 1.
          20
 
Item 1A.
20
 
Item 2.
21
 
Item 3.
21
 
Item 4.
21
 
Item 5.
21
 
Item 6.
21
22

Cautionary Note about Forward-Looking Statements

This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue, liquidity or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services, products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.  Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words.  The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions.  Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Current Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019.  We disclaim any obligation to update any forward looking statements as a result of developments occurring after the date of this quarterly report.

Unless the context requires otherwise, references to “we,” “us,” “our” and “the Company” refer to RiceBran Technologies and its consolidated subsidiaries.

2
PART I.
FINANCIAL INFORMATION

Item 1.
Financial Statements.

RiceBran Technologies
Condensed Consolidated Statements of Operations
Three and Nine Months Ended September 30, 2020 and 2019
(Unaudited) (in thousands, except share and per share amounts)

   
Three Months Ended
    
Nine Months Ended
  
   
2020
    
2019
    
2020
    
2019
  
                         
Revenues
  
$
5,160
    
$
5,300
    
$
19,393
    
$
17,883
  
Cost of goods sold
    
5,955
      
5,659
      
21,817
      
18,143
  
Gross loss
    
(795
)
    
(359
)
    
(2,424
)
    
(260
)
Selling, general and administrative expenses
    
1,875
      
3,835
      
7,040
      
10,598
  
Operating loss
    
(2,670
)
    
(4,194
)
    
(9,464
)
    
(10,858
)
Other income (expense):
                                
Interest income
    
-
      
19
      
19
      
42
  
Interest expense
    
(70
)
    
(9
)
    
(195
)
    
(40
)
Other income
    
-
      
859
      
5
      
865
  
Other expense
    
(26
)
    
(1
)
    
(113
)
    
(5
)
Total other income (expense), net
    
(96
)
    
868
      
(284
)
    
862
  
Loss before income taxes
    
(2,766
)
    
(3,326
)
    
(9,748
)
    
(9,996
)
Income tax expense
    
(8
)
    
-
      
(8
)
    
-
  
Loss from continuing operations
    
(2,774
)
    
(3,326
)
    
(9,756
)
    
(9,996
)
Loss from discontinued operations
    
-
      
-
      
-
      
(216
)
Net loss
  
$
(2,774
)
  
$
(3,326
)
  
$
(9,756
)
  
$
(10,212
)
                                 
Basic loss per common share:
                                
Continuing operations
  
$
(0.07
)
  
$
(0.10
)
  
$
(0.24
)
  
$
(0.31
)
Discontinued operations
    
-
      
-
      
-
      
(0.01
)
Basic loss per common share
  
$
(0.07
)
  
$
(0.10
)
  
$
(0.24
)
  
$
(0.32
)
                                 
Diluted loss per common share:
                                
Continuing operations
  
$
(0.07
)
  
$
(0.10
)
  
$
(0.24
)
  
$
(0.31
)
Discontinued operations
    
-
      
-
      
-
      
(0.01
)
Diluted loss per common share
  
$
 (0.07
)
  
$
(0.10
)
  
$
(0.24
)
  
$
(0.32
)
                                 
Weighted average number of shares outstanding:
  
Basic
    
40,824,281
      
33,057,010
      
40,279,866
      
31,947,087
  
Diluted
    
40,824,281
      
33,057,010
      
40,279,866
      
31,947,087
  

See Notes to Unaudited Condensed Consolidated Financial Statements

3
RiceBran Technologies
Condensed Consolidated Statements of Comprehensive Loss
Three and Nine Months Ended September 30, 2020 and 2019
(Unaudited) (in thousands)

   
Three Months Ended
    
Nine Months Ended
  
   
2020
    
2019
    
2020
    
2019
  
                         
Net loss
  
$
(2,774
)
  
$
(3,326
)
  
$
(9,756
)
  
$
(10,212
)
                                 
Derivative financial instruments designated as cash flow hedges:
                                
Gains (losses) arising during the period
    
43
      
-
      
(57
)
    
-
  
Reclassification of losses realized to cost of goods sold
    
5
      
-
      
57
      
-
  
Net other comprehensive income
    
48
      
-
      
-
      
-
  
                                 
Comprehensive loss
  
$
(2,726
)
  
$
(3,326
)
  
$
(9,756
)
  
$
(10,212
)

See Notes to Unaudited Condensed Consolidated Financial Statements

4
RiceBran Technologies
Condensed Consolidated Balance Sheets
(Unaudited) (in thousands, except share amounts)

    
September 30,
2020
    
December 31,
2019
  
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
3,890
    
$
8,444
  
Accounts receivable, net of allowance for doubtful accounts of $23 and $347
    
2,446
      
3,738
  
Inventories
    
1,665
      
898
  
Other current assets
    
1,619
      
691
  
Total current assets
    
9,620
      
13,771
  
Property and equipment, net
    
17,289
      
19,077
  
Operating lease right-of-use assets
    
2,527
      
2,752
  
Goodwill
    
3,915
      
3,915
  
Intangible assets
    
777
      
950
  
Other long-term assets
    
-
      
27
  
Total assets
  
$
34,128
    
$
40,492
  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
                
Current liabilities:
                
Accounts payable
  
$
845
    
$
833
  
Commodities payable
    
554
      
829
  
Accrued salary, wages and benefits
    
879
      
877
  
Accrued expenses
    
439
      
884
  
Customer prepayments
    
-
      
12
  
Operating lease liabilities, current portion
    
334
      
309
  
Due under insurance premium finance agreements
    
327
      
116
  
Due under factoring agreement
    
1,814
      
1,823
  
Finance lease liabilities, current portion
    
89
      
101
  
Long-term debt, current portion
    
575
      
28
  
Total current liabilities
    
5,856
      
5,812
  
Operating lease liabilities, less current portion
    
2,403
      
2,674
  
Finance lease liabilities, less current portion
    
132
      
190
  
Long-term debt, less current portion
    
2,264
      
73
  
Total liabilities
    
10,655
      
8,749
  
Commitments and contingencies
                
Shareholders' equity:
                
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225,225 shares, issued and outstanding
    
112
      
112
  
Common stock, no par value, 150,000,000 shares authorized, 41,972,594 shares and 40,074,483 shares, issued and outstanding
    
320,297
      
318,811
  
Accumulated deficit
    
(296,936
)
    
(287,180
)
Total shareholders' equity
    
23,473
      
31,743
  
Total liabilities and shareholders' equity
  
$
34,128
    
$
40,492
  

See Notes to Unaudited Condensed Consolidated Financial Statements

5
RiceBran Technologies
Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2020 and 2019
(Unaudited) (in thousands)

   
2020
    
2019
  
Cash flow from operating activities:
            
Net loss
  
$
(9,756
)
  
$
(10,212
)
Loss from discontinued operations
    
-
      
216
  
Loss from continuing operations
    
(9,756
)
    
(9,996
)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities
          
Depreciation
    
1,804
      
1,332
  
Amortization
    
173
      
39
  
Stock and share-based compensation
    
817
      
925
  
Loss on disposition of property and equipment
    
305
      
-
  
Loss on involuntary conversion of assets
    
100
      
-
  
Settlement with sellers of Golden Ridge
    
-
      
(849
)
Other
    
(18
)
    
166
  
Changes in operating assets and liabilities, net of impact of acquisitions:
                
Accounts receivable
    
1,360
      
(215
)
Inventories
    
(767
)
    
388
  
Accounts payable and accrued expenses
    
(651
)
    
(271
)
Commodities payable
    
(275
)
    
(1,896
)
Other
    
(320
)
    
(308
)
Net cash used in operating activities
    
(7,228
)
    
(10,685
)
Cash flows from investing activities:
                
Purchases of property and equipment
    
(1,060
)
    
(3,513
)
Proceeds from insurance on involuntary converison
    
250
      
-
  
Proceeds from sale of property
    
15
      
-
  
Acquisition of MGI
    
-
      
(3,767
)
Net cash used in investing activities - continuing operations
    
(795
)
    
(7,280
)
Net cash used in investing activities - discontinued operations
    
-
      
(475
)
Cash flows from financing activities:
                
Payments on factoring agreement
    
(20,663
)
    
-
  
Advances on factoring agreement
    
20,584
      
-
  
Advances on insurance premium finance agreements
    
802
      
643
  
Payments on insurance premium finance agreements
    
(591
)
    
(415
)
Advances on debt and finance lease liabilities
    
2,792
      
-
  
Payments on debt and finance lease liabilities
    
(124
)
    
(331
)
Proceeds from issuances of common stock and prefunded warrant, net of issuance costs
    
657
      
11,593
  
Proceeds from common stock warrant exercises
    
12
      
1,990
  
Proceeds from common stock option exercises
    
-
      
156
  
Proceeds from margin loan
    
-
      
1,225
  
Net cash provided by financing activities
    
3,469
      
14,861
  
Net change in cash and cash equivalents and restricted cash
  
$
(4,554
)
  
$
(3,579
)
                 
Cash and cash equivalents and restricted cash, beginning of period
                
Cash and cash equivalents
  
$
8,444
    
$
7,044
  
Restricted cash
    
-
      
225
  
Cash and cash equivalents and restricted cash, beginning of period
    
8,444
      
7,269
  
Cash and cash equivalents and restricted cash, end of period
                
Cash and cash equivalents
    
3,890
      
3,690
  
Restricted cash
    
-
      
-
  
Cash and cash equivalents and restricted cash, end of period
    
3,890
      
3,690
  
Net change in cash and cash equivalents and restricted cash
  
$
(4,554
)
  
$
(3,579
)
                 
Supplemental disclosures:
                
Cash paid for interest
  
$
126
    
$
40
  
Cash paid for income taxes
  
$
7
    
$
-
  

See Notes to Unaudited Condensed Consolidated Financial Statements

6
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 1. BASIS OF PRESENTATION

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business. 

NOTE 2. BUSINESS

We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products.

In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans.  Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition.  Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas.  At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes.  Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice.  We also own a grain processing facility in East Grand Forks, Minnesota, at which we mill a variety of grains which we offer to the market.

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.
 
7
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.

Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

Derivative Financial Instruments

In May 2020, we began, from time to time, to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.

NOTE 4. ACQUISITION

On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI). The results of MGI’s operations are included in our consolidated financial statements beginning April 4, 2019.  The following table provides unaudited pro forma information for the three months and nine months ended September 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

   
Three Months Ended
September 30, 2019
    
Nine Months Ended
September 30, 2019
  
Revenues (in thousands)
  
$
5,300
    
$
19,083
  
Loss from continuing operations (in thousands)
  
$
(3,326
)
  
$
(9,865
)
Loss per share - continuing operations
  
$
(0.10
)
  
$
(0.31
)
Weighted average number of common shares outstanding - basic and diluted
    
33,057,010
      
31,947,087
  

No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition.  The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2019, or of our future operating results.

NOTE 5. CASH AND CASH EQUIVALENTS

As of September 30, 2020, we have $2.4 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements.  We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

We have cash on deposit in excess of federally insured limits at a bank.  We do not believe that maintaining substantially all such assets with the bank or investing in a liquid money market fund represent material risks.

8
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES

Amounts billed and due from our customers are classified as accounts receivable on our consolidated balance sheets and require payment on a short-term basis. Invoices are generally issued at the point control transfers and substantially all of our invoices are due within 30 days or less, however certain customers have terms of up to 120 days.  For substantially all of our contracts, control of the ordered product(s) transfers at our location.  Periodically, we require payment prior to the point in time we recognize revenue.  Amounts received from customers prior to revenue recognition on a contract are contract liabilities, are classified as customer prepayments liability on our consolidated balance sheets and are typically applied to an invoice within 30 days of the prepayment.  Revenues in the three and nine months ended September 30, 2020, include less than $0.1 million in revenue unearned as of December 31, 2019.

Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

   
Customer


 
A

 
B
   
C
    D

% of revenues, three months ended September 30, 2020
    
6
%
    
12
%
    
11
%
    
4
%
% of revenues, three months ended September 30, 2019
    
10
%
    
13
%
    
11
%
    
3
%
                                 
% of revenues, nine months ended September 30, 2020
    
11
%
    
10
%
    
5
%
    
3
%
% of revenues, nine months ended September 30, 2019
    
14
%
    
11
%
    
10
%
    
1
%
                                 
% of accounts receivable, as of September 30, 2020
    
5
%
    
19
%
    
12
%
    
10
%
% of accounts receivable, as of December 31, 2019
    
31
%
    
10
%
    
8
%
    
10
%

In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

   
Three Months Ended September 30
    
Nine Months Ended September 30
  
   
2020
    
2019
    
2020
    
2019
  
Food
  
$
3,160
    
$
3,573
    
$
13,319
    
$
12,685
  
Animal nutrition
    
2,000
      
1,727
      
6,074
      
5,198
  
Revenues
  
$
5,160
    
$
5,300
    
$
19,393
    
$
17,883
  

NOTE 7. INVENTORIES

The following table details the components of inventories (in thousands).

     
September 30,
2020
      
December 31,
2019
   
Finished goods
  
$
1,363
    
$
698
  
Raw materials
    
180
      
90
  
Packaging
    
122
      
110
  
Inventories
  
$
1,665
    
$
898
  

9
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 8. LEASES

The components of lease expense and cash flows from leases (in thousands) follow.

   
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
   
2020
    
2019
    
2020
    
2019
  
Finance lease cost:
                        
Amortization of right-of use assets, included in cost of goods sold
  
$
21
    
$
19
    
$
62
    
$
50
  
Interest on lease liabilities
    
3
      
5
      
11
      
10
  
Operating lease cost, included in selling, general and administrative expenses:
                                
Fixed leases cost
    
127
      
131
      
388
      
392
  
Variable lease cost
    
41
      
35
      
89
      
99
  
Short-term lease cost
    
-
      
13
      
3
      
29
  
Total lease cost
  
$
192
    
$
203
    
$
553
    
$
580
  
                                 
Cash paid for amounts included in the measurement of lease liabilities:
                                
Operating cash flows from finance leases
  
$
3
    
$
5
    
$
11
    
$
10
  
Operating cash flows from operating leases
  
$
127
    
$
131
    
$
388
    
$
392
  
Financing cash flows from finance leases
  
$
29
    
$
23
    
$
75
    
$
54
  

As of September 30, 2020, variable lease payments do not depend on a rate or index.  As of September 30, 2020, property and equipment, net, includes $0.3 million of finance lease right-of-use-assets, with an original cost of $0.4 million.

As of September 30, 2020, we do not believe it is certain that we will exercise any renewal options.  The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of September 30, 2020, follows.

   
Operating
Leases
    
Finance
Leases
  
Remaining leases terms (in years)
    
3.1-12.4
      
0.3-3.8
  
Weighted average remaining lease terms (in years)
    
7.2
      
2.7
  
Discount rates
    
6.3%-9.0
%
    
4.3%-7.3
%
Weighted average discount rate
    
7.6
%
    
5.9
%

Maturities of lease liabilities as of September 30, 2020, follows (in thousands).

     
Operating
Leases
      
Finance
Leases
   
2020 (three months ended December 31, 2020)
  
$
116
    
$
28
  
2021
    
536
      
91
  
2022
    
548
      
68
  
2023
    
528
      
38
  
2024
    
428
      
11
  
Thereafter
    
1,468
      
-
  
Total lease payments
    
3,624
      
236
  
Amounts representing interest
    
(887
)
    
(15
)
Present value of lease obligations
  
$
2,737
    
$
221
  

NOTE 9. DEBT

In the three and nine months ended September 30, 2020, we financed amounts owed for annual insurance premiums under financing agreements.  As of September 30, 2020, amounts due under insurance premium financing agreements are due in monthly installments of principal and interest through January 2021, at interest rates of 4.7% to 5.5% per year. 

10
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender.  We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement.  The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given.  We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years.  We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed.  During the three and nine months ended September 30, 2020, outstanding borrowings under the agreement averaged $1.7 million and $1.9 million per day, respectively.  During the three months ended September 30, 2020, we expensed less than $0.1 million of interest and fees under the agreement.  On an annualized basis, fees incurred during the three months ending September 30, 2020 averaged 5.6% (exclusive of deferred cost amortization) and interest averaged 6.0% of the amounts outstanding under the facility. During the nine months ended September 30, 2020, we expensed $0.2 million of interest and fees under the agreement. On an annualized basis, fees incurred during the nine months ending September 30, 2020 averaged 7.9% (exclusive of deferred cost amortization) and interest averaged 6.3% of the amounts outstanding under the facility. Amortization of debt issuance costs in the nine months ended September 30, 2020, was $0.1 million.  The lender has the right to demand repayment of the advances at any time.

Due under factoring agreement consists of the following (in thousands).

     
September 30,
2020
      
December 31,
2019
   
Borrowings outstanding
  
$
1,912
    
$
1,989
  
Debt issuance costs, net
    
(98
)
    
(166
)
Due under factoring agreement
  
$
1,814
    
$
1,823
  

Long-term debt consists of the following (in thousands).

    
September 30,
2020
    
December 31,
2019
  
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
            
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
  
$
1,792
    
$
-
  
Mortgage promissory note - Dated September 2020.  Interest accrues at an annual rate which is the greater of 11.0% above the lender's prime rate and 14.3%.  Payable in monthly installments through June 2022.
    
985
      
-
  
Debt issuance costs, net - Related to mortgage promissory note dated September 2020
    
(15
)
    
-
  
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year, which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments.
Expire at dates ranging through 2022.
    
43
      
62
  
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
                
Interest accrues at the effective discount rate of 9.3% per year.
    
34
      
39
  
Total long term debt, net
  
$
2,839
    
$
101
  

In April 2020, we received $1.8 million on an SBA Payroll Protection Program loan as provided for in the Coronavirus Aid, Relief and Economic Security Act (CARES), enacted into U.S. law in March 2020.  Under certain conditions, the loan and accrued interest are forgivable, specifically, if the loan proceeds were used for eligible purposes, including payroll, benefits, rent and utilities, and maintaining payroll levels.  The amount of loan forgiveness will be reduced if we terminated employees or reduced salaries during the applicable period.  Any portion of the loan that is not forgiven is payable over two years at an interest rate of 1.0%, with a deferral of payments for the first six months.  We believe we have used the proceeds for purposes consistent with the program.  As such, we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, however, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part.

In July 2020, we entered into a mortgage agreement with a lender pursuant to a promissory note.  In September 2020, we borrowed $1.0 million on the note and, in October 2020, we borrowed the remaining $1.0 million available on the note.  Interest on this note accrues at an annual rate which is the greater of 11.0% above the lender’s prime rate and 14.3%.  In addition, we will incur a facility fee equal to 1.0% of the amount of each advance under the promissory note.  The principal amount of the note must be repaid in monthly installments ending in June 2022.  The note is secured by certain real property and personal property assets of Golden Ridge Rice Mill, Inc.  As of September 30, 2020, the note bore interest at an annual rate of 14.3%.

11
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

In June 2020, our shareholders approved, and we filed an amendment to our articles of incorporation, increasing our authorized shares of common stock from 50,000,000 to 150,000,000.

A summary of equity activity follows (in thousands, except share amounts).

   
Shares
                

   
Accumulated Other
         
     
Preferred
Series G
         
Common
      
Preferred
Stock
      
Common
Stock
      
Accumulated
Deficit
      
Comprehensive
Loss
        
Equity
   
Balance, December 31, 2019
    
225
      
40,074,483
    
$
112
    
$
318,811
    
$
(287,180
)
  
$
-
    
$
31,743
  
Common stock awards under equity incentive plans
    
-
      
17,534
      
-
      
312
      
-
      
-
      
312
  
Net loss
    
-
      
-
      
-
      
-
      
(3,033
)
    
-
      
(3,033
)
Balance, March 31, 2020
    
225
      
40,092,017
      
112
      
319,123
      
(290,213
)
    
-
      
29,022
  
Common stock awards under equity incentive plans
    
-
      
16,500
      
-
      
316
      
-
      
-
      
316
  
Common stock issued to vendors
    
-
      
31,304
      
-
      
36
      
-
      
-
      
36
  
Exercise of common stock warrants
    
-
      
67,577
      
-
      
12
      
-
      
-
      
12
  
Other comprehensive loss
    
-
      
-
      
-
      
-
      
-
      
(48
)
    
(48
)
Net loss
    
-
      
-
      
-
      
-
      
(3,949
)
    
-
      
(3,949
)
Balance, June 30, 2020
    
225
      
40,207,398
      
112
      
319,487
      
(294,162
)
    
(48
)
    
25,389
  
Common stock awards under equity incentive plans
    
-
      
129,404
      
-
      
153
      
-
      
-
      
153
  
Sale of common stock, net of costs
    
-
      
1,635,792
      
-
      
657
      
-
      
-
      
657
  
Other comprehensive income
    
-
      
-
      
-
      
-
      
-
      
48
      
48
  
Net loss
    
-
      
-
      
-
      
-
      
(2,774
)
    
-
      
(2,774
)
Balance, September  30, 2020
    
225
      
41,972,594
    
$
112
    
$
320,297
    
$
(296,936
)
  
$
-
    
$
23,473
  

   
Shares
                    
    
Preferred
Series G
    
Common
    
Preferred
Stock
    
Common
Stock
    
Accumulated
Deficit
    
Equity
  
Balance, December 31, 2018
    
405
      
29,098,207
    
$
201
    
$
296,739
    
$
(273,229
)
  
$
23,711
  
Sale of common stock and Prefunded Warrant, net of costs
    
-
      
3,046,668
      
-
      
11,593
      
-
      
11,593
  
Common stock awards under equity incentive plans
    
-
      
36,881
      
-
      
364
      
-
      
364
  
Exercise of common stock warrants
    
-
      
600,000
      
-
      
1,980
      
-
      
1,980
  
Conversion of preferred stock into common stock
    
(180
)
    
170,818
      
(89
)
    
89
      
-
      
-
  
Exercise of common stock options
    
-
      
77,078
      
-
      
60
      
-
      
60
  
Other
    
-
      
-
      
-
      
28
      
-
      
28
  
Net loss
    
-
      
-
      
-
      
-
      
(3,227
)
    
(3,227
)
Balance, March 31, 2019
    
225
      
33,029,652
      
112
      
310,853
      
(276,456
)
    
34,509
  
Exercise of Prefunded Warrant
    
-
      
1,003,344
      
-
      
10
      
-
      
10
  
Common stock awards under equity incentive plans
    
-
      
134,984
      
-
      
219
      
-
      
219
  
Exercise of common stock options
    
-
      
78,734
      
-
      
87
      
-
      
87
  
Other
    
-
      
-
      
-
      
32
      
-
      
32
  
Net loss
    
-
      
-
      
-
      
-
      
(3,659
)
    
(3,659
)
Balance, June 30, 2019
    
225
      
34,246,714
      
112
      
311,201
      
(280,115
)
    
31,198
  
Retirement of unvested shares
    
-
      
(830,124
)
    
-
      
-
      
-
      
-
  
Common stock awards under equity incentive plans
    
-
      
22,632
      
-
      
282
      
-
      
282
  
Exercise of common stock options
    
-
      
10,000
      
-
      
9
      
-
      
9
  
Retirement of shares received in settlement with the sellers of Golden Ridge
    
-
      
(340,000
)
    
-
      
(1,027
)
    
-
      
(1,027
)
Net loss
    
-
      
-
      
-
      
-
      
(3,326
)
    
(3,326
)
Balance, September  30, 2019
    
225
      
33,109,222
    
$
112
    
$
310,465
    
$
(283,441
)
  
$
27,136
  

12
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent.  The issuances and sales of our common stock under the agreement are made pursuant to our effective “shelf” registration statement on Form S-3.  During the three months ended September 30, 2020, we issued and sold 1,635,792 shares of common stock under the agreement, at an average price of $0.50 per share.  Proceeds from those sales are recorded in equity, net of $0.2 million of stock issuance costs.  Stock issuance costs consisted of $0.1 million of legal, advisor and auditor expenses paid in the three months ended March 31, 2020, and $0.1 million of other costs related to the offering paid in the three months ended September 30, 2020.

Share-based compensation by type of award follows (in thousands).

   
Three Months Ended
        
   
Sept. 30, 2020
    
June 30, 2020
    
March 31, 2020
  
Common stock, vested and nonvested at issuance
  
$
78
    
$
95
    
$
105
  
Stock options
    
(86
)
    
99
      
85
  
Restricted stock units
    
161
      
122
      
122
  
Compensation expense related to common stock awards issued under equity incentive plan
   $
153
     $
316
     $
312
  


In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period.

In the three months ended June 30, 2020, under the equity incentive plan, we (i) issued 16,500 shares of common stock, vested at June 30, 2020, at a grant date fair value or $1.16 per shares and (ii) recognized $0.1 million of expense for shares of common stock vesting during the period.  In the three months ended June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share.

In the three months ended September 30 2020, we issued (i) 42,383 shares of common stock, vested at issuance, to a consultant at an average grant date fair value of $0.53 per share, (ii) 32,510 shares of common stock, vested at issuance, to a director for board compensation at an average grant date fair value of $0.45 per share, and (iii) 54,511 shares of common stock, vested at issuance, to our former chief executive officer for employment compensation and severance at an average grant date fair value of $0.76 per share,

As of September 30, 2020, there were no shares of nonvested common stock outstanding.

Stock option activity for the nine months ended September 30, 2020, follows.

   
Shares
Under
Options
    
Weighted
Average
Exercise
Price
    
Weighted
Average
Grant
Date Fair
Value
    
Weighted
Average
Remaining
Contractual
Life (Years)
  
Outstanding at December 31, 2019
    
996,009
    
$
3.23
            
8.1
  
Granted
    
653,004
      
1.22
    
$
0.73
      
10.0
  
Forfeited
    
(125,173
)
    
4.74
              
7.2
  
Outstanding at March 31, 2020
    
1,523,840
      
2.24
              
8.8
  
Forfeited
    
(77,357
)
    
4.28
              
7.2
  
Outstanding at June 30, 2020
    
1,446,483
    
$
2.13
              
8.6
  
Forfeited
    
(654,334
)
    
1.97
              
8.8
  
Outstanding at September 30, 2020
    
792,149
    
$
2.27
              
8.1
  

Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants.

13
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Restricted stock unit (RSU) activity for the nine months ended September 30, 2020, follows.

   
RSU Shares
Issued to
Employees
and
Directors
    
Unrecognized
Stock
Compensation
(in thousands)
    
Weighted
Average
Expense
Period
(Years)
  
Nonvested at December 31, 2019
    
1,148,062
    
$
377
      
1.4
  
Cancelled
    
(625,000
)
    
-
          
Forfeited (1)
    
(175,000
)
    
(142
)
        
Expensed (2)
    
-
      
(122
)
        
Nonvested at March 31, 2020
    
348,062
      
113
      
1.2
  
Granted to directors (3)
    
477,018
      
426
          
Forfeited (1)
    
(30,000
)
    
(24
)
        
Vested (4)
    
(115,904
)
    
-
          
Expensed
    
-
      
(122
)
        
Nonvested at June 30, 2020
    
679,176
      
393
      
0.8
  
Granted to directors (3)
    
189,284
      
87
          
Granted to consultant (3)
    
89,286
      
38
          
Forfeited (1)
    
(91,000
)
    
(55
)
        
Vested (4)
    
(189,284
)
    
-
          
Expensed
    
-
      
(161
)
        
Nonvested at September 30, 2020 (5)(6)
    
677,462
      
302
      
0.5
  

 
(1)
We reversed $0.2 million of expense recognized in prior periods on forfeited RSU shares in the amounts indicated in the unrecognized stock compensation column.
 
(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares in the three months ended March 31, 2020.
 
(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(4)
Represents shares of common stock subject to RSUs which were vested when granted.
 
(5)
RSUs for a total of 450,400 shares of common stock vest in June 2021 and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(6)
A total of 227,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 22,706 shares on the date the vesting price equals or exceeds $5.00 per share, (ii) 68,119 shares on the date the vesting price equals or exceeds $10.00 per share and (iii) 136,237 shares on the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.

14
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

Warrant activity for the nine months ended September 30, 2020, follows.

   
Shares
Under
Warrants
        
Weighted
Average
Exercise
Price
    
Weighted
Average
Remaining
Contractual
Life (Years)
  
                   
Outstanding, Decembver 31, 2019
    
7,532,280
    
$
1.32
      
1.9
  
Expired
    
(265,000
)
    
5.25
      
-
  
Outstanding, March 31, 2020
    
7,267,280
      
1.18
      
1.7
  
Cash exercised
    
(12,948
)
    
0.96
      
-
  
Cashless exercised (1)
    
(215,740
)
    
0.96
      
-
  
Expired
    
(392,676
)
    
4.60
      
-
  
Outstanding, June 30, 2020
    
6,645,916
    
$
0.98
      
1.7
  
Outstanding, Septemeber 30, 2020 (2)
    
6,645,916
    
$
0.98
      
1.4
  

 
(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
 
(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of September 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.

NOTE 11. INVOLUNTARY CONVERSION OF ASSETS

In September 2020, we wrote down assets, consisting primarily of a building, machinery and equipment, in the amount of $0.9 million and incurred other costs of $0.1 million as a result of hurricane damage that occurred in August 2020. This event damaged our Lake Charles, Louisiana property, and operations at that facility were shut down in September 2020.  We expect insurance recoveries will cover our asset loss to the extent it exceeds our $0.1 million deductible under our insurance policy.  In September 2020, we received an advance on the insurance settlement of $0.3 million and we accrued a receivable for the additional $0.7 million of expected insurance proceeds related to our asset loss.  The resulting $0.1 million net loss on involuntary conversion of assets is included in selling, general and administrative expenses in our consolidated financial statements.   The insurance proceeds receivable is included in other current assets on our consolidated balance sheets.  The final settlement with the insurer on this matter will likely differ from the total proceeds we estimated as of September 30, 2020.  We accrue estimated insurance proceeds receivable when the proceeds are estimable and probable of collection.  Given the nature of recoveries of lost profits under business interruption insurance we have not accrued insurance proceeds receivable for any potential recoveries of lost profits under our insurance policy.

NOTE 12. INCOME TAXES

Our tax expense for the three and nine months ended September 30, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S.  As of September 30, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards.  We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist.  Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law.  A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made.

15
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

CARES, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment.  Except for the impact of the loan we received under the act, see Note 9, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.

NOTE 13. LOSS PER SHARE (EPS)

Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends.  Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive.  The dilutive effects of outstanding options, warrants, nonvested shares of common stock and nonvested restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method.  The dilutive effects of the outstanding preferred stock are calculated using the if-converted method.

Below are reconciliations of the numerators and denominators in the EPS computations.

   
Three Months Ended September 30
    
Nine Months Ended September 30
  
   
2020
    
2019
    
2020
    
2019
  
NUMERATOR (in thousands):
                        
Basic and diluted - loss from continuing operations
  
$
(2,774
)
  
$
(3,326
)
  
$
(9,756
)
  
$
(9,996
)
                                 
DENOMINATOR:
                                
Weighted average number of shares of shares of common stock outstanding
    
40,691,824
      
33,057,010
      
40,232,289
      
31,947,087
  
Weighted average number of shares of common stock underlying vested restricted stock units
    
132,457
      
-
      
47,577
      
-
  
Basic EPS - weighted average number of shares outstanding
    
40,824,281
      
33,057,010
      
40,279,866
      
31,947,087
  
Effect of dilutive securities outstanding
    
-
      
-
      
-
      
-
  
Diluted EPS - weighted average number of shares outstanding
    
40,824,281
      
33,057,010
      
40,279,866
      
31,947,087
  

No effects of potentially dilutive securities outstanding during the three and nine months ended September 30, 2020 and 2019, were included in the calculation of diluted EPS for the three and nine months ended September 30, 2020 and 2019, because to do so would be anti-dilutive as a result of our loss from continuing operations.  Potentially dilutive securities outstanding during the periods included our outstanding convertible preferred stock, options, warrants, nonvested restricted stock units and nonvested stock.  Those potentially dilutive securities, further described in Note 10, could potentially dilute EPS in the future.

NOTE 14. FAIR VALUE MEASUREMENTS

Derivative financial instruments are carried at fair value, on a recurring basis, in accumulated OCI, and fair value is based on the quoted prices of the financial instruments (Level 1 measurements).  The fair value of cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, commodities payable and short-term debt approximated their carrying value due to shorter maturities.  As of September 30, 2020, the fair value of our operating lease liabilities was approximately $0.2 million higher than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).  As of September 30, 2020, the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

NOTE 15. COMMITMENTS AND CONTINGENCIES

Employment Contracts and Severance Payments

In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions.  While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions.  No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

16
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control.  In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

Legal Matters

From time to time we are involved in litigation incidental to the conduct of our business.  These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations.  When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Defense costs are expensed as incurred and are included in professional fees.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations, except for a contract dispute to be settled between July 2020 and October 2020.   In the three and nine months ended September 30, 2020, we recognized $0.5 million and $0.7 million, respectively, in cost of goods sold related to the resolution of the contract dispute as it relates to contract periods through September 30, 2020.

NOTE 16. RELATED PARTY TRANSACTIONS

Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC).  As of the date of this filing, CGC owns approximately 25.4% of our outstanding common stock.  We have agreed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors.  In March 2019, we issued and sold to CGC 666,667 shares of common stock at a purchase price of $3.00 per share and a prefunded warrant exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement.  The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before CGC could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding.  CGC exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019. 

NOTE 17.  TRANSACTIONS WITH EMPLOYEES

During the three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison.  As of September 30, 2020, and December 31, 2019, no amounts were owed to these entities. 

NOTE 18. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS

On July 27, 2020, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).  Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00.  To regain compliance with this listing rule, the closing bid price of our common stock must be at least $1.00 for 10 consecutive business days.  We have a period of 180 calendar days from the date of notification, or until January 25, 2021, to regain compliance.  If this appears unlikely as January 25, 2021, approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1.00 minimum bid price.

17
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
Results of Operations

Unless otherwise noted, amounts and percentages for all periods discussed below reflect the results of operations and financial condition from our continuing operations.

Three Months Ended September 30, 2020 Compared to Three Months Ended September 30, 2019

Revenues decreased $0.1 million in the third quarter of 2020 to $5.2 million compared to $5.3 million in the third quarter of 2019.  The decrease in revenue year-over-year was due to lower revenues at our Golden Ridge Rice Mill (Golden Ridge) operations, which ran well below capacity for most of the third quarter as we were not able to acquire sufficient rough rice to mill at an economical price.  Lower revenues from Golden Ridge was partially offset by increases in revenue from both our MGI Grain (MGI) and our RiceBran (RBT) businesses.

We experienced a gross loss of $0.8 million in the third quarter of 2020 compared to a gross loss of $0.4 million in the third quarter of 2019.  The increase in gross loss was primarily attributable to Golden Ridge due to higher input commodity prices, $0.5 million in expenses related to the resolution of contract disputes, and the impact of higher downtime during the quarter compared to the same period a year ago. Gross losses were also impacted by negative operating leverage from a shift in product mix versus a year ago.

Selling, general and administrative (SG&A) expenses were $1.9 million in the third quarter of 2020, compared to $3.9 million in the third quarter of 2019, a decrease of $2.0 million.  The decline in SG&A expense was primarily related to initiatives to reduce overall SG&A costs, which we began enacting in the first quarter of 2020. SG&A was impacted favorably by the reversal of approximately $0.1 million in previously recognized stock compensation when unvested awards were forfeited, offset by a $0.1 million loss due to hurricane damage to a facility in Louisiana in 2020.

Other net was $0.1 million in the third quarter of 2020 compared to other income, net, of $0.9 million in 2019.  In the 2020 period, we incurred higher fees and interest expense related to the increased average outstanding balance of our factoring facility, a new facility entered into in the fourth quarter of 2019, and on our long-term debt borrowings under agreements entered into in 2020, described further in Note 9 of the Notes to Unaudited Condensed Consolidated Financial Statements. The 2019 period included $0.8 million gain from a settlement with the sellers of Golden Ridge which was of a nonrecurring nature.

Nine Months Ended September 30, 2020 Compared to Nine Months Ended September 30, 2019

Revenues increased $1.5 million, or 8.4%, in the first nine months of 2020 compared to the first nine months of 2019.  The increase in revenue year over year was due to higher revenues from MGI and Golden Ridge, offset by a decline in revenue from our RBT operations.   MGI was acquired in April 2019 and, therefore, our revenues included no MGI revenue in the first quarter of 2019.

We experienced a gross loss of $2.4 million in the first nine months of 2020, compared to a gross loss of $0.3 million in the first nine months of 2019.  The decline in gross profit was primarily attributable to higher losses from Golden Ridge due to sub-par milling yields, higher input commodity prices, $0.7 million in expenses related to the resolution of contract disputes, and negative operating leverage from higher downtime in the second and third quarters.  Gross profits were also negatively impacted by negative operating leverage from our RBT operations, offset in part by a higher gross profit contribution from MGI.

SG&A expenses were $7.0 million in the first nine months of 2020, compared to $10.6 million in the first nine months of 2019, a decrease of $3.6 million.  The decline in SG&A expenses was primarily related to initiatives to reduce overall SG&A costs, which we began enacting in the first quarter of 2020, as well as the absence of approximately $0.3 million in costs associated with our acquisition of Golden Ridge, and lower legal and outside accounting fees. These reductions were offset by a $0.1 million loss due to hurricane damage to a facility in in Louisiana and a $0.3 million loss on disposition of assets in 2020.

Other net was $0.3 million in the first nine months of 2020 compared to other income, net, of $0.9 million in the first nine months of 2019.  In the 2020 period, we incurred higher fees and interest expense related to the increased average outstanding balance of our factoring facility, a new facility entered in to in the fourth quarter of 2019, and on our long-term debt borrowings under agreements entered into in 2020.  The 2019 period included $0.8 million gain from a settlement with the sellers of Golden Ridge which was of a nonrecurring nature.

18
COVID-19 Assessment

The United States is experiencing an outbreak of a novel coronavirus (COVID-19), which has been declared a "pandemic" by the World Health Organization.

The COVID-19 pandemic has become a worldwide health crisis that is adversely affecting the economies and financial markets of many countries, which we expect may adversely affect the demand for our products.   This pandemic also poses the risk that we or our customers, suppliers and other business partners may be disrupted or prevented from conducting business activities for certain periods of time, the durations of which are uncertain.  However, we are not able to estimate the exact magnitude of the impact of such developments on our business.  The extent of the impact of COVID-19 on our business and financial results will depend on future developments, including the duration and spread of the outbreak within the markets in which we operate, including the related impact on our customers’ spending, all of which is highly uncertain.

In April 2020, we applied for, and received, a $1.8 million SBA Paycheck Protection Program loan as discussed further in Note 9 of the Notes to Unaudited Condensed Consolidated Financial Statements.  We believe the funds from this loan have enabled us to maintain our current workforce in light of potential economic disruptions to our business resulting from the COVID-19 outbreak.

We currently do not expect any of our facilities to be subject to government-mandated closures, and we have informed our customers that, at this time, we anticipate operating throughout the COVID-19 outbreak.  The COVID-19 outbreak has not yet caused any material disruption in the supply of raw materials used in our products or in the distribution of our products, and to date, our employees have been reporting to work, either remotely or in-person without any material changes in attendance or productivity due to the COVID-19 outbreak. However, we cannot ensure that the COVID-19 outbreak will not cause disruptions to our business in the future.

Liquidity, Going Concern and Capital Resources

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million.  As further discussed in Note 10 of the Notes to Unaudited Condensed Consolidated Financial Statements, we received net proceeds of $0.7 million under the agreement.  As discussed further in Note 9 of the Notes to Unaudited Condensed Consolidated Financial Statements, in April 2020, we were approved for a $1.8 million SBA Payroll Protection Program loan (PPP Loan) and in July 2020, we secured a mortgage of up to $2.0 million on our rice mill in Wynne, Arkansas.  We received $1.0 million of proceeds under the mortgage in September 2020 and an additional $1.0 million in October 2020.

We used $7.3 million in operating cash during the first nine months of 2020.  We used operating cash to increase our inventories by $0.8 million in anticipation of early October product shipments.  We experienced a $1.4 million reduction in accounts receivable in the first nine months of 2020 associated with the decrease in revenues at the end of the third quarter of 2020.  We paid $1.1 million of capital expenditures in the first nine months of 2020.  We expect to fund the rebuilding of our building in Louisiana with proceeds from insurance.  We funded our working capital needs in the nine months ended September 30, 2020 primarily with funds received from the sale of receivables under our factoring agreement, supplemented by proceeds from the PPP loan, mortgage note and stock offering.

Management believes that despite the multi-year history of operating losses and negative operating cash flows from our continuing operations, there is no substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. The factors that alleviated this doubt include cash and cash equivalents of $3.9 million as of September 30, 2020, the resumption of operations and the end of payments to settle prior contract disputes at our Golden Ridge facility, positive revenue and margin trends for our RiceBran and MGI operations, a nearly 50% year-over-year reduction in corporate expenses, and the ability to seek addition capital through asset-backed borrowing arrangements and/or asset dispositions.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, other than employee contracts, that have or are likely to have a current or future material effect on our financial condition, changes in financial condition, revenue, expenses, results of operations, liquidity, capital expenditures, or capital resources.

19
Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.  The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements.  On an ongoing basis, we evaluate the estimates, including, but not limited to, those related to revenue recognition.  We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments.  Actual results could differ from those estimates.

Recent Accounting Pronouncements

See Note 3 in the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion.

Item 3.
Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4.
Controls and Procedures 

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosures.

We evaluated, with the participation of our chief executive officer, and chief financial officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q.  Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.
OTHER INFORMATION

Item 1.
Legal Proceedings

We are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings and investigations in the ordinary course of business.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows.  We record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.

Item 1A.
Risk Factors

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, which could materially affect our business, financial condition, liquidity or future results.  The risks described in our Annual Report on Form 10-K are not the only risks facing our company.  Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results.

20
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent.  The issuances and sales of our common stock under the agreement are made pursuant to our effective “shelf” registration statement on Form S-3.  During the three months ended September 30, 2020, we issued and sold 1,635,792 shares of common stock under the agreement, at an average price of $0.50 per share, for total proceeds of $818,929.  During the quarter ended September 30, 2020, we paid the sales agent a 5% commission totaling $40,946 and $213 of SEC and other fees.  In prior quarters we paid $120,767 for legal and other fees associated with the offering, including $50,000 reimbursed the sales agent for its legal fees.  The net proceeds from this offering, after deducting the sales agent’s commissions and other offering expenses, were used for general and administrative expenses and other general corporate purposes.

Item 3.
Defaults upon Senior Securities

None

Item 4.
Mine Safety Disclosures

None

Item 5.
Other Information

None

Item 6.
Exhibits

The following exhibits are attached hereto and filed herewith:

 
 
 
 
Incorporated by Reference
 
 
Exhibit
Number
 
Exhibit Description
 
Form
 
File No.
 
Exhibit
Number
 
Filing/Effective
Date
 
Filed
Here-with
                         
 
Certificate of Amendment of Articles of Incorporation filed with the Secretary of State of California on June 18, 2020
  
10-Q
  
001-36245
  
3.1
  
August 12, 2020
    
 
Mortgage Agreement and Amendment for Purchase and Sale with Republic Business Credit, LLC
  
8-K
  
001-36245
  
10.1
  
July 17, 2020
    
10.4 (2)
  
Severance Agreement with Brent R. Rystrom
                  
X
 
Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
              
 
X
 
Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
              
 
X
 
Certification by CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
              
 
X
101.INS (1)
 
XBRL Instance Document
 
              
 
X
101.SCH (1)
 
XBRL Taxonomy Extension Schema Document
 
              
 
X
101.CAL (1)
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
              
 
X
101.DEF (1)
 
XBRL Taxonomy Extension Calculation Definition Linkbase Document
 
              
 
X
101.LAB (1)
 
XBRL Taxonomy Extension Calculation Label Linkbase Document
 
              
 
X
101.PRE (1)
 
XBRL Taxonomy Extension Calculation Presentation Linkbase Document
 
              
 
X

 
(1)
XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
 
(2)
Indicates a management contract or compensatory plan, contract or arrangement.

21
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated:  November 5, 2020
 
 
 
 
 
 
/s/ Peter G. Bradley
 
 
Peter G. Bradley
  
 
Executive Chairman
 
 
/s/ Todd T. Mitchell
 
 
Todd T. Mitchell
  
 
Chief Financial Officer


22
Exhibit 10.4

SEVERANCE AND RELEASE AGREEMENT

This Severance and Release Agreement (“Agreement”) is entered into by and between RiceBran Technologies, a California corporation (“RBT”), and Brent R. Rystrom, an individual (“Employee”), and is effective as of August 14, 2020 (“Effective Date”).  The parties agree as follows:

1.          Background and Purpose.  On October 12, 2018, Employee and RBT entered into an Amended and Restated Employment Agreement regarding the terms of Employee’s employment with RBT (“Employment Agreement”). The parties have agreed that Employee’s employment with RBT is terminated as of the Effective Date and that Employee will provide certain consulting services for RBT following the Effective Date as provided below.  In accordance with the terms of the Employment Agreement, Employee has agreed to release all claims against RBT.

2.             Employment Termination; Separation Payments. Employee’s employment with RBT shall terminate as of the Effective Date. Forthwith upon the Effective Date, RBT shall make all payments due from the period June 17, 2020 through the Effective Date, for compensation and benefits, including the delivery of stock certificate(s) evidencing the issuance of common stock in payment of compensation, in the manner and fashion as agreed and specified in the minutes of the meeting of the Board of Directors on June 17, 2020. Additionally, RBT shall pay Employee a cash lump sum payment equal to all previously accrued but unpaid compensation for unused vacation leave accruing through and including the Effective Date (344 hours equaling $55.404.64). In addition, within ten (10) days following the Effective Date, RBT shall pay Employee the Base Salary (as defined in the Employment Agreement) that Employee would have been paid had he remained employed with RBT for the ninety (90) day period following the Effective Date.

3.            Consulting Services; Benefits.  For a period not to extend beyond December 31, 2020, following the Effective Date, Employee agrees to be reasonably available during normal business hours to provide consulting and transition services for RBT as reasonably required by RBT with regard to the operations of the RBT business. During this period, RBT shall provide (or pay the premium expense pursuant to COBRA eligibility) continuing health care and insurance benefits at the same levels as provided by RBT for Employee immediately prior to the Effective Date. Employee will be paid for such consulting services, as set forth on Exhibit 1 attached hereto and made a part hereof. It is expressly understood and agreed that RBT will not share material non-public information to Employee, nor shall Employee be required to provide consultative services in connection with any matter that might involve the use or dissemination of material non-public information.

4.         Return of Property.  On the Effective Date, Employee agrees to surrender all RBT property, documentation, or information, in his possession or under his control including, but not limited to RBT files, notes, drawings, memoranda, records, business plans and forecasts, reports, proposals, personnel information, financial information, specifications, computer-recorded information, tangible property (laptop computer, mobile phone, iPad, etc.), entry cards, identification badges and keys; and, any materials of any kind that contain or embody any proprietary or confidential information of RBT (and all reproductions thereof in whole or in part). Employee agrees that he will not copy or download any files or programs from RBT’s computer or take or retain any other RBT property with him on the Effective Date.

-1-
5.            Post-Employment Restrictions; Proprietary Information and Non-Solicitation.  Employee acknowledges and agrees that the Proprietary Information Agreement dated March 8, 2017 between RBT and Employee remains in full force and effect. Without limiting the requirements of such agreement, Employee agrees to refrain from disclosing or using, for himself or others, any of RBT’s proprietary trade secret information. Employee represents that he has held all RBT confidential information confidential and will continue to do so.  Employee further acknowledge and agrees that the non-solicitation provisions of Section 2.5 of the Employment Agreement are and shall remain in full force and effect for a period of two (2) years after the Effective Date.  Nothing contained herein waives or limits any rights of RBT with respect to the Proprietary Information Agreement or Section 2.5 of the Employment Agreement.

6.            Non-Disparagement.  Employee and RBT each agree not to disparage or defame the other party, or its officers, directors, employees, shareholders or agents, as applicable, in any manner likely to be harmful to it or him, or its or his business, business reputation or personal reputation; provided that either party may respond accurately and fully to any question, inquiry or request for information to the extent required by applicable law.

7.            Release of Claims. Each of Employee and RBT (“Releasing Party”) hereby knowingly, voluntarily, and irrevocably releases and discharges the other party, its officers, directors, trustees, agents, representatives, attorneys, servants, employees, predecessors, successors, subsidiaries, parents, divisions, other corporate affiliates and their spouses, heirs, personal representatives, and assigns, and all persons or entities acting by, through, under, or in concert with any of them (collectively “Released Parties”) from any and all claims, demands, liabilities, judgments, damages, expenses, or causes of action of any kind or nature whatsoever (“Claims”) that the Releasing Party, his or its heirs, personal representatives, and assigns, and each of them, may have had, may now or hereafter have to assert, whether now known or unknown, including but not limited to breach of express or implied contract; breach of the covenant of good faith and fair dealing. Without limiting the foregoing, Employee specifically releases RBT from any and all Claims for wrongful discharge; public policy torts of any kind or nature; discrimination on the basis of age, sex, religion, disability, race, or any other reason prohibited by applicable law; claims under the Age discrimination in Employment Act (“ADEA”), Title VII of the Civil Rights Act of 1964, the Fair Labor Standards Act, the Equal Pay Act, the Employee Retirement Income Security Act of 1974, the Americans with Disabilities Act, the Worker Adjustment and Retraining Notification Act, and all applicable state laws, all as amended, or any other federal, state or local law, regulation, ordinance, or executive or administrative order; tort claims of any kind whatsoever; any other common law or statutory claims, claims for salary, wages, vacation pay, severance pay, bonus payments, commission payments, stock options except for those already vested and not yet exercised until they expire by their terms, or earnings of any kind, fringe benefits, medical or hospital expenses or benefits, litigation expenses, attorneys’ fees, employment reinstatement, compensatory damages of any kind, liquidated or statutory damages, and any other amounts; any and all other damages arising out of or connected in any way whatsoever with the employment of Employee by Released Parties, or any of them, at any time before the date of this Agreement, or with the termination of such employment.  The Releasing Party further warrants that he or it has not filed or asserted or transferred or assigned any cause of action released herein to any other person or entity prior to the signing of this Agreement and that he or it shall not do so.  the Releasing Party agrees to indemnify and hold Released Parties harmless against any claim, including attorneys’ fees actually paid or incurred, arising out of or in any way connected with any such filing, assertion, assignment or transfer or any such purported or claimed assignment or transfer. Pursuant to the terms of the Older Workers' Benefit Protection Act (“OWBPA”), Employee is waiving any claims he may have under ADEA arising prior to the date he/she executes this agreement.  Employee acknowledges that he has had twenty-one (21) days in which to consider the terms of this waiver.  Employee acknowledges that, by the terms of this Agreement, he has been advised in writing that the he should consult with an attorney regarding the terms and conditions of this Agreement.  Employee further acknowledges that, by the terms of this Agreement, he has been advised that following execution of this Agreement, he has seven (7) days in which he may revoke his/her waiver pursuant to the OWBPA and that this Agreement does not become effective with respect to the release of any OWBPA claims until the seventh (7th) day following execution of the Agreement.  Any notice of revocation of this Agreement must be sent to: RiceBran Technologies, Attention Brent Rosenthal, 1330 Lake Robbins Drive, Suite 250, The Woodlands, Texas 977380.  The date, seven (7) days following the execution of this Agreement, shall be the effective date of the release of OWBPA claims under this Agreement.  Employee further acknowledges that he has consulted with an attorney and is fully aware of the rights and claims being released by his execution of this Agreement.  Employee hereby acknowledges that the waiver of claims under ADEA is only in exchange for consideration in addition to anything of value to which Employee is already entitled.  By signing this Agreement, Employee does not waive rights or claims under the ADEA that may arise after the date that this Agreement is signed.

-2-
8.           Resolution of Disputes. Any claim or controversy arising out of or pertaining to this Agreement, the Employment Agreement or the termination of Employee’s employment, including but not limited to, claims of wrongful treatment or termination allegedly resulting from discrimination, harassment or retaliation on the basis of race, sex, age, national origin, ancestry, color, religion, marital status, status as a veteran of the Vietnam era, physical or mental disability, medical condition, or any other basis prohibited by law (“Dispute”)  shall be resolved by binding arbitration as provided in Section 8.8 of the Employment Agreement, which Section remains in full force and effect for this purpose.

9.             Entire Agreement; Waiver; Amendment.  This document, the Proprietary Information Agreement and the surviving terms of the Employment Agreement specified herein constitute the entire agreement between the parties, all oral agreements being merged herein and therein, and supersedes all prior representations and agreements.  There are no representations, agreements, arrangements, or understandings, oral or written, between or among the parties relating to the subject matter of this Agreement that are not fully expressed herein or therein. Any of the terms or conditions of this Agreement may be waived at any time by the party entitled to the benefit thereof, but no such waiver shall affect or impair the right of the waiving party to require observance, performance or satisfaction either of that term or condition as it applies on a subsequent occasion or of any other term or condition hereof. The provisions of this Agreement may be modified or amended at any time by agreement of the parties.  Any such amendment or modification as hereinafter may be made, shall be ineffective to modify this Agreement in any respect unless in writing and signed by the party or parties against whom enforcement of the modification or amendment is sought.

10.          Severability.  If any provision of this Agreement is adjudicated by a court of competent jurisdiction to be invalid or unenforceable, the remainder of the Agreement which can be given full force and effect without the invalid provision shall continue in full force and effect and shall in no way be impaired or invalidated.

11.         Succession; No Assignment.  Subject to the provisions otherwise contained in this Agreement, this Agreement shall inure to the benefit of, and be binding upon, the successors and assigns of each of the respective parties hereto. This Agreement shall not be assigned by any party without the prior written consent of the other party. Any assignment contrary to the provisions of this Agreement shall be deemed a default under the Agreement, allowing the non-defaulting party to exercise all remedies available under law.

-3-
12.         Notices.  Any notice under this Agreement shall be provided in accordance with Section 8.3 of the Employment Agreement.

13.          Counterparts; Electronic Signatures.  The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one-in-the-same document. The words “execute,” “execution,” “signed”, “signature,” and words of like import in this Agreement shall be deemed to include electronic signatures, including photographs of electronic signatures, sent via text and/or email

14.        Compliance with IRC Section 409A.  This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) or an exemption thereunder and shall be construed and administered in accordance with Section 409A.  Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption.  Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible.  Any payments to be made under this Agreement upon a termination of employment shall only be made if such termination of employment constitutes a “separation from service” under Section 409A.  Notwithstanding the foregoing, RBT makes no representations that the payments and benefits provided under this Agreement comply with Section 409A and in no event shall RBT be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Employee on account of non-compliance with Section 409A.

[Signature Page to Follow]

-4-
The parties have entered into this Severance and Release Agreement as of the Effective Date first set forth above.

RICEBRAN TECHNOLOGIES,
    
a California corporation
    
     
/s/ Brent Rosenthal   /s/ Brent R. Rystrom
By:
 Brent Rosenthal  
By:
 Brent R. Rystrom
Title:
 Chairman of the Board of Directors    
     
Address:
 1330 Lake Robbins Drive, Suite 250   Address:    

The Woodlands, Texas 977380        

-5-
Exhibit 1

Calculation of Compensation for Consulting Services:

From a gross payment of $12,844.62, there shall be a deduction for the value of benefits paid (as hereinabove referenced) or the cost of COBRA premiums paid by RBT on behalf of Employee for the period from the Effective Date through December 31, 2020 to arrive at a “Net Amount.”*

Employee will receive shares of common stock of RBT; the number of shares to be equal in value to the aforementioned “Net Amount.”  The shares of stock shall be issued on or before August 31, 2020.

*In the event of the discontinuation of payment of COBRA premiums prior to 12/31/20, the parties agree to make adjustments to allow for the issuance of additional shares reflective of the pro rata reduction in premiums actually paid.


-6-
Exhibit 31.1

Certification of Principal Executive Officer
 Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Peter G. Bradley, certify that:

1)
I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated: November 5, 2020
 /s/ Peter G. Bradley
 
 
 
  
 
Name: Peter G. Bradley
 
Title: Executive Chairman
 

Exhibit 31.2

Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd T. Mitchell, certify that:

1)
I have reviewed this quarterly report on Form 10-Q of RiceBran Technologies;

2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:  November 5, 2020
/s/ Todd T. Mitchell
 
 
 
  
 
Name: Todd T. Mitchell
 
Title: Chief Financial Officer


Exhibit 32.1

Certification of Principal Executive Officer and Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with the Quarterly Report on Form 10-Q of RiceBran Technologies (the “Company”) for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Company.
 
Dated:  November 5, 2020
 
 
 
 
 
 
/s/ Peter G. Bradley
  
 
Peter G. Bradley
  
 
Executive Chairman
 
 
/s/ Todd T. Mitchell
 
 
Todd T. Mitchell
  
 
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished in accordance with Securities and Exchange Commission Release No. 34-47551 and shall not be considered filed as part of the Form 10-Q.


v3.20.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2020
Nov. 02, 2020
Cover [Abstract]    
Entity Registrant Name RiceBran Technologies  
Entity Central Index Key 0001063537  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   41,972,594
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2020  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Entity Address, State or Province TX  
v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Condensed Consolidated Statements of Operations (Unaudited) [Abstract]        
Revenues $ 5,160 $ 5,300 $ 19,393 $ 17,883
Cost of goods sold 5,955 5,659 21,817 18,143
Gross loss (795) (359) (2,424) (260)
Selling, general and administrative expenses 1,875 3,835 7,040 10,598
Operating loss (2,670) (4,194) (9,464) (10,858)
Other income (expense):        
Interest income 0 19 19 42
Interest expense (70) (9) (195) (40)
Other income 0 859 5 865
Other expense (26) (1) (113) (5)
Total other income (expense), net (96) 868 (284) 862
Loss before income taxes (2,766) (3,326) (9,748) (9,996)
Income tax expense (8) 0 (8) 0
Loss from continuing operations (2,774) (3,326) (9,756) (9,996)
Loss from discontinued operations 0 0 0 (216)
Net loss $ (2,774) $ (3,326) $ (9,756) $ (10,212)
Basic loss per common share:        
Continuing operations (in dollars per share) $ (0.07) $ (0.10) $ (0.24) $ (0.31)
Discontinued operations (in dollars per share) 0 0 0 (0.01)
Basic loss per common share (in dollars per share) (0.07) (0.10) (0.24) (0.32)
Diluted loss per common share:        
Continuing operations (in dollars per share) (0.07) (0.10) (0.24) (0.31)
Discontinued operations (in dollars per share) 0 0 0 (0.01)
Diluted loss per common share (in dollars per share) $ (0.07) $ (0.10) $ (0.24) $ (0.32)
Weighted average number of shares outstanding:        
Basic (in shares) 40,824,281 33,057,010 40,279,866 31,947,087
Diluted (in shares) 40,824,281 33,057,010 40,279,866 31,947,087
v3.20.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) [Abstract]        
Net loss $ (2,774) $ (3,326) $ (9,756) $ (10,212)
Derivative financial instruments designated as cash flow hedges:        
Gains (losses) arising during the period 43 0 (57) 0
Reclassification of losses realized to cost of goods sold 5 0 57 0
Net other comprehensive income 48 0 0 0
Comprehensive loss $ (2,726) $ (3,326) $ (9,756) $ (10,212)
v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 3,890 $ 8,444
Accounts receivable, net of allowance for doubtful accounts of $23 and $347 2,446 3,738
Inventories 1,665 898
Other current assets 1,619 691
Total current assets 9,620 13,771
Property and equipment, net 17,289 19,077
Operating lease right-of-use assets 2,527 2,752
Goodwill 3,915 3,915
Intangible assets 777 950
Other long-term assets 0 27
Total assets 34,128 40,492
Current liabilities:    
Accounts payable 845 833
Commodities payable 554 829
Accrued salary, wages and benefits 879 877
Accrued expenses 439 884
Customer prepayments 0 12
Operating lease liabilities, current portion 334 309
Due under insurance premium finance agreements 327 116
Due under factoring agreement 1,814 1,823
Finance lease liabilities, current portion 89 101
Long-term debt, current portion 575 28
Total current liabilities 5,856 5,812
Operating lease liabilities, less current portion 2,403 2,674
Finance lease liabilities, less current portion 132 190
Long-term debt, less current portion 2,264 73
Total liabilities 10,655 8,749
Commitments and contingencies
Shareholders' equity:    
Common stock, no par value, 150,000,000 shares authorized, 41,972,594 shares and 40,074,483 shares, issued and outstanding 320,297 318,811
Accumulated deficit (296,936) (287,180)
Total shareholders' equity 23,473 31,743
Total liabilities and shareholders' equity 34,128 40,492
Series G Convertible Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $225, 225 shares, issued and outstanding $ 112 $ 112
v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 23 $ 347
Shareholders' equity:    
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 41,972,594 40,074,483
Common stock, shares outstanding (in shares) 41,972,594 40,074,483
Series G Convertible Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, shares authorized (in shares) 3,000 3,000
Preferred stock, stated value $ 225 $ 225
Convertible preferred stock, shares issued (in shares) 225 225
Convertible preferred stock, shares outstanding (in shares) 225 225
v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flow from operating activities:    
Net loss $ (9,756) $ (10,212)
Loss from discontinued operations 0 216
Loss from continuing operations (9,756) (9,996)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities    
Depreciation 1,804 1,332
Amortization 173 39
Stock and share-based compensation 817 925
Loss on disposition of property and equipment 305 0
Loss on involuntary conversion of assets 100 0
Settlement with sellers of Golden Ridge 0 (849)
Other (18) 166
Changes in operating assets and liabilities, net of impact of acquisitions:    
Accounts receivable 1,360 (215)
Inventories (767) 388
Accounts payable and accrued expenses (651) (271)
Commodities payable (275) (1,896)
Other (320) (308)
Net cash used in operating activities (7,228) (10,685)
Cash flows from investing activities:    
Purchases of property and equipment (1,060) (3,513)
Proceeds from insurance on involuntary conversion 250 0
Proceeds from sale of property 15 0
Acquisition of MGI 0 (3,767)
Net cash used in investing activities - continuing operations (795) (7,280)
Net cash used in investing activities - discontinued operations 0 (475)
Cash flows from financing activities:    
Payments on factoring agreement (20,663) 0
Advances on factoring agreement 20,584 0
Advances on insurance premium finance agreements 802 643
Payments on insurance premium finance agreements (591) (415)
Advances on debt and finance lease liabilities 2,792 0
Payments on debt and finance lease liabilities (124) (331)
Proceeds from issuances of common stock and prefunded warrant, net of issuance costs 657 11,593
Proceeds from common stock warrant exercises 12 1,990
Proceeds from common stock option exercises 0 156
Proceeds from margin loan 0 1,225
Net cash provided by financing activities 3,469 14,861
Net change in cash and cash equivalents and restricted cash (4,554) (3,579)
Cash and cash equivalents and restricted cash, beginning of period    
Cash and cash equivalents 8,444 7,044
Restricted cash 0 225
Cash and cash equivalents and restricted cash, beginning of period 8,444 7,269
Cash and cash equivalents and restricted cash, end of period    
Cash and cash equivalents 3,890 3,690
Restricted cash 0 0
Cash and cash equivalents and restricted cash, end of period 3,890 3,690
Supplemental disclosures:    
Cash paid for interest 126 40
Cash paid for income taxes $ 7 $ 0
v3.20.2
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2020
BASIS OF PRESENTATION [Abstract]  
BASIS OF PRESENTATION
NOTE 1. BASIS OF PRESENTATION

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business. 
v3.20.2
BUSINESS
 9 Months Ended
Sep. 30, 2020
BUSINESS [Abstract]  
BUSINESS
NOTE 2. BUSINESS

We are a specialty ingredient company focused on producing value-added processing and marketing of healthy, natural and nutrient dense products derived from rice and other small grains, and the by-products created in the milling of these grains. Notably, we apply our proprietary technologies to convert raw rice bran into stabilized rice bran (SRB), and high value derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product; and a variety of other valuable derivatives extracted from these core products.

In granular form, SRB is a food additive used in the production of products for both human and animal consumption. We believe SRB has certain inherent qualities that make it more attractive for this purpose than food additives based on the by-products of other agricultural commodities, such as corn and soybeans.  Our SRB and refined SRB products and derivatives support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods, and high-end animal nutrition.  Our target customers are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally.

We manufacture and distribute SRB in various granulations from four locations: two leased facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; one company-owned facility in Mermentau, Louisiana; and our company-owned rice mill in Wynne, Arkansas.  At our Dillon, Montana facility, we produce SRB based products and derivatives that have been further refined through our proprietary processes.  Our rice mill in Wynne, Arkansas also supplies grades U.S. No. 1 and No. 2 premium long and medium white rice.  We also own a grain processing facility in East Grand Forks, Minnesota, at which we mill a variety of grains which we offer to the market.
v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.
 
Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.

Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

Derivative Financial Instruments

In May 2020, we began, from time to time, to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.
v3.20.2
ACQUISITION
 9 Months Ended
Sep. 30, 2020
ACQUISITION [Abstract]  
ACQUISITION
NOTE 4. ACQUISITION

On April 4, 2019, we acquired substantially all of the assets comprising the business of MGI Grain Processing, LLC, a Minnesota limited liability company, now conducting business as MGI Grain Incorporated (MGI). The results of MGI’s operations are included in our consolidated financial statements beginning April 4, 2019.  The following table provides unaudited pro forma information for the three months and nine months ended September 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

  
Three Months Ended
September 30, 2019
  
Nine Months Ended
September 30, 2019
 
Revenues (in thousands)
 
$
5,300
  
$
19,083
 
Loss from continuing operations (in thousands)
 
$
(3,326
)
 
$
(9,865
)
Loss per share - continuing operations
 
$
(0.10
)
 
$
(0.31
)
Weighted average number of common shares outstanding - basic and diluted
  
33,057,010
   
31,947,087
 

No adjustments have been made in the pro forma information for synergies that are resulting or planned from the MGI acquisition.  The unaudited proforma information is not indicative of the results that may have been achieved had the companies been combined as of January 1, 2019, or of our future operating results.
v3.20.2
CASH AND CASH EQUIVALENTS
 9 Months Ended
Sep. 30, 2020
CASH AND CASH EQUIVALENTS [Abstract]  
CASH AND CASH EQUIVALENTS
NOTE 5. CASH AND CASH EQUIVALENTS

As of September 30, 2020, we have $2.4 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements.  We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

We have cash on deposit in excess of federally insured limits at a bank.  We do not believe that maintaining substantially all such assets with the bank or investing in a liquid money market fund represent material risks.
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES
 9 Months Ended
Sep. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]  
ACCOUNTS RECEIVABLE AND REVENUES
NOTE 6. ACCOUNTS RECEIVABLE AND REVENUES

Amounts billed and due from our customers are classified as accounts receivable on our consolidated balance sheets and require payment on a short-term basis. Invoices are generally issued at the point control transfers and substantially all of our invoices are due within 30 days or less, however certain customers have terms of up to 120 days.  For substantially all of our contracts, control of the ordered product(s) transfers at our location.  Periodically, we require payment prior to the point in time we recognize revenue.  Amounts received from customers prior to revenue recognition on a contract are contract liabilities, are classified as customer prepayments liability on our consolidated balance sheets and are typically applied to an invoice within 30 days of the prepayment.  Revenues in the three and nine months ended September 30, 2020, include less than $0.1 million in revenue unearned as of December 31, 2019.

Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

  
Customer


 
A


 
B

  
C

  D

% of revenues, three months ended September 30, 2020
  
6
%
  
12
%
  
11
%
  
4
%
% of revenues, three months ended September 30, 2019
  
10
%
  
13
%
  
11
%
  
3
%
                 
% of revenues, nine months ended September 30, 2020
  
11
%
  
10
%
  
5
%
  
3
%
% of revenues, nine months ended September 30, 2019
  
14
%
  
11
%
  
10
%
  
1
%
                 
% of accounts receivable, as of September 30, 2020
  
5
%
  
19
%
  
12
%
  
10
%
% of accounts receivable, as of December 31, 2019
  
31
%
  
10
%
  
8
%
  
10
%

In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

  
Three Months Ended September 30
  
Nine Months Ended September 30
 
  
2020
  
2019
  
2020
  
2019
 
Food
 
$
3,160
  
$
3,573
  
$
13,319
  
$
12,685
 
Animal nutrition
  
2,000
   
1,727
   
6,074
   
5,198
 
Revenues
 
$
5,160
  
$
5,300
  
$
19,393
  
$
17,883
 
v3.20.2
INVENTORIES
 9 Months Ended
Sep. 30, 2020
INVENTORIES [Abstract]  
INVENTORIES
NOTE 7. INVENTORIES

The following table details the components of inventories (in thousands).

    
September 30,
2020
    
December 31,
2019
  
Finished goods
 
$
1,363
  
$
698
 
Raw materials
  
180
   
90
 
Packaging
  
122
   
110
 
Inventories
 
$
1,665
  
$
898
 
v3.20.2
LEASES
 9 Months Ended
Sep. 30, 2020
LEASES [Abstract]  
LEASES
NOTE 8. LEASES

The components of lease expense and cash flows from leases (in thousands) follow.

  
Three Months Ended September 30,
  
Nine Months Ended September 30,
 
  
2020
  
2019
  
2020
  
2019
 
Finance lease cost:
            
Amortization of right-of use assets, included in cost of goods sold
 
$
21
  
$
19
  
$
62
  
$
50
 
Interest on lease liabilities
  
3
   
5
   
11
   
10
 
Operating lease cost, included in selling, general and administrative expenses:
                
Fixed leases cost
  
127
   
131
   
388
   
392
 
Variable lease cost
  
41
   
35
   
89
   
99
 
Short-term lease cost
  
-
   
13
   
3
   
29
 
Total lease cost
 
$
192
  
$
203
  
$
553
  
$
580
 
                 
Cash paid for amounts included in the measurement of lease liabilities:
                
Operating cash flows from finance leases
 
$
3
  
$
5
  
$
11
  
$
10
 
Operating cash flows from operating leases
 
$
127
  
$
131
  
$
388
  
$
392
 
Financing cash flows from finance leases
 
$
29
  
$
23
  
$
75
  
$
54
 

As of September 30, 2020, variable lease payments do not depend on a rate or index.  As of September 30, 2020, property and equipment, net, includes $0.3 million of finance lease right-of-use-assets, with an original cost of $0.4 million.

As of September 30, 2020, we do not believe it is certain that we will exercise any renewal options.  The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of September 30, 2020, follows.

  
Operating
Leases
  
Finance
Leases
 
Remaining leases terms (in years)
  
3.1-12.4
   
0.3-3.8
 
Weighted average remaining lease terms (in years)
  
7.2
   
2.7
 
Discount rates
  
6.3%-9.0
%
  
4.3%-7.3
%
Weighted average discount rate
  
7.6
%
  
5.9
%

Maturities of lease liabilities as of September 30, 2020, follows (in thousands).

    
Operating
Leases
    
Finance
Leases
  
2020 (three months ended December 31, 2020)
 
$
116
  
$
28
 
2021
  
536
   
91
 
2022
  
548
   
68
 
2023
  
528
   
38
 
2024
  
428
   
11
 
Thereafter
  
1,468
   
-
 
Total lease payments
  
3,624
   
236
 
Amounts representing interest
  
(887
)
  
(15
)
Present value of lease obligations
 
$
2,737
  
$
221
 
v3.20.2
DEBT
 9 Months Ended
Sep. 30, 2020
DEBT [Abstract]  
DEBT
NOTE 9. DEBT

In the three and nine months ended September 30, 2020, we financed amounts owed for annual insurance premiums under financing agreements.  As of September 30, 2020, amounts due under insurance premium financing agreements are due in monthly installments of principal and interest through January 2021, at interest rates of 4.7% to 5.5% per year. 

In October 2019, we entered into a factoring agreement which provides for a $7.0 million credit facility with a lender.  We may only borrow to the extent we have qualifying accounts receivable as defined in the agreement.  The facility has an initial two-year term and automatically renews for successive annual periods, unless proper termination notice is given.  We paid a $0.2 million facility fee upon inception of the agreement which is amortizing to interest expense on a straight-line basis over two years.  We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances and a service fee on average net funds borrowed.  During the three and nine months ended September 30, 2020, outstanding borrowings under the agreement averaged $1.7 million and $1.9 million per day, respectively.  During the three months ended September 30, 2020, we expensed less than $0.1 million of interest and fees under the agreement.  On an annualized basis, fees incurred during the three months ending September 30, 2020 averaged 5.6% (exclusive of deferred cost amortization) and interest averaged 6.0% of the amounts outstanding under the facility. During the nine months ended September 30, 2020, we expensed $0.2 million of interest and fees under the agreement. On an annualized basis, fees incurred during the nine months ending September 30, 2020 averaged 7.9% (exclusive of deferred cost amortization) and interest averaged 6.3% of the amounts outstanding under the facility. Amortization of debt issuance costs in the nine months ended September 30, 2020, was $0.1 million.  The lender has the right to demand repayment of the advances at any time.

Due under factoring agreement consists of the following (in thousands).

    
September 30,
2020
    
December 31,
2019
  
Borrowings outstanding
 
$
1,912
  
$
1,989
 
Debt issuance costs, net
  
(98
)
  
(166
)
Due under factoring agreement
 
$
1,814
  
$
1,823
 

Long-term debt consists of the following (in thousands).

   
September 30,
2020
  
December 31,
2019
 
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
      
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
 
$
1,792
  
$
-
 
Mortgage promissory note - Dated September 2020.  Interest accrues at an annual rate which is the greater of 11.0% above the lender's prime rate and 14.3%.  Payable in monthly installments through June 2022.
  
985
   
-
 
Debt issuance costs, net - Related to mortgage promissory note dated September 2020
  
(15
)
  
-
 
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year, which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments.
Expire at dates ranging through 2022.
  
43
   
62
 
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
        
Interest accrues at the effective discount rate of 9.3% per year.
  
34
   
39
 
Total long term debt, net
 
$
2,839
  
$
101
 

In April 2020, we received $1.8 million on an SBA Payroll Protection Program loan as provided for in the Coronavirus Aid, Relief and Economic Security Act (CARES), enacted into U.S. law in March 2020.  Under certain conditions, the loan and accrued interest are forgivable, specifically, if the loan proceeds were used for eligible purposes, including payroll, benefits, rent and utilities, and maintaining payroll levels.  The amount of loan forgiveness will be reduced if we terminated employees or reduced salaries during the applicable period.  Any portion of the loan that is not forgiven is payable over two years at an interest rate of 1.0%, with a deferral of payments for the first six months.  We believe we have used the proceeds for purposes consistent with the program.  As such, we currently believe that our use of the loan proceeds will meet the conditions for forgiveness of the loan, however, we cannot assure that we will be eligible for forgiveness of the loan, in whole or in part.

In July 2020, we entered into a mortgage agreement with a lender pursuant to a promissory note.  In September 2020, we borrowed $1.0 million on the note and, in October 2020, we borrowed the remaining $1.0 million available on the note.  Interest on this note accrues at an annual rate which is the greater of 11.0% above the lender’s prime rate and 14.3%.  In addition, we will incur a facility fee equal to 1.0% of the amount of each advance under the promissory note.  The principal amount of the note must be repaid in monthly installments ending in June 2022.  The note is secured by certain real property and personal property assets of Golden Ridge Rice Mill, Inc.  As of September 30, 2020, the note bore interest at an annual rate of 14.3%.
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS
 9 Months Ended
Sep. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]  
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS
NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

In June 2020, our shareholders approved, and we filed an amendment to our articles of incorporation, increasing our authorized shares of common stock from 50,000,000 to 150,000,000.

A summary of equity activity follows (in thousands, except share amounts).

  
Shares
        

  
Accumulated Other
     
    
Preferred
Series G
      
Common
    
Preferred
Stock
    
Common
Stock
    
Accumulated
Deficit
    
Comprehensive
Loss
     
Equity
  
Balance, December 31, 2019
  
225
   
40,074,483
  
$
112
  
$
318,811
  
$
(287,180
)
 
$
-
  
$
31,743
 
Common stock awards under equity incentive plans
  
-
   
17,534
   
-
   
312
   
-
   
-
   
312
 
Net loss
  
-
   
-
   
-
   
-
   
(3,033
)
  
-
   
(3,033
)
Balance, March 31, 2020
  
225
   
40,092,017
   
112
   
319,123
   
(290,213
)
  
-
   
29,022
 
Common stock awards under equity incentive plans
  
-
   
16,500
   
-
   
316
   
-
   
-
   
316
 
Common stock issued to vendors
  
-
   
31,304
   
-
   
36
   
-
   
-
   
36
 
Exercise of common stock warrants
  
-
   
67,577
   
-
   
12
   
-
   
-
   
12
 
Other comprehensive loss
  
-
   
-
   
-
   
-
   
-
   
(48
)
  
(48
)
Net loss
  
-
   
-
   
-
   
-
   
(3,949
)
  
-
   
(3,949
)
Balance, June 30, 2020
  
225
   
40,207,398
   
112
   
319,487
   
(294,162
)
  
(48
)
  
25,389
 
Common stock awards under equity incentive plans
  
-
   
129,404
   
-
   
153
   
-
   
-
   
153
 
Sale of common stock, net of costs
  
-
   
1,635,792
   
-
   
657
   
-
   
-
   
657
 
Other comprehensive income
  
-
   
-
   
-
   
-
   
-
   
48
   
48
 
Net loss
  
-
   
-
   
-
   
-
   
(2,774
)
  
-
   
(2,774
)
Balance, September  30, 2020
  
225
   
41,972,594
  
$
112
  
$
320,297
  
$
(296,936
)
 
$
-
  
$
23,473
 

  
Shares
          
   
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Equity
 
Balance, December 31, 2018
  
405
   
29,098,207
  
$
201
  
$
296,739
  
$
(273,229
)
 
$
23,711
 
Sale of common stock and Prefunded Warrant, net of costs
  
-
   
3,046,668
   
-
   
11,593
   
-
   
11,593
 
Common stock awards under equity incentive plans
  
-
   
36,881
   
-
   
364
   
-
   
364
 
Exercise of common stock warrants
  
-
   
600,000
   
-
   
1,980
   
-
   
1,980
 
Conversion of preferred stock into common stock
  
(180
)
  
170,818
   
(89
)
  
89
   
-
   
-
 
Exercise of common stock options
  
-
   
77,078
   
-
   
60
   
-
   
60
 
Other
  
-
   
-
   
-
   
28
   
-
   
28
 
Net loss
  
-
   
-
   
-
   
-
   
(3,227
)
  
(3,227
)
Balance, March 31, 2019
  
225
   
33,029,652
   
112
   
310,853
   
(276,456
)
  
34,509
 
Exercise of Prefunded Warrant
  
-
   
1,003,344
   
-
   
10
   
-
   
10
 
Common stock awards under equity incentive plans
  
-
   
134,984
   
-
   
219
   
-
   
219
 
Exercise of common stock options
  
-
   
78,734
   
-
   
87
   
-
   
87
 
Other
  
-
   
-
   
-
   
32
   
-
   
32
 
Net loss
  
-
   
-
   
-
   
-
   
(3,659
)
  
(3,659
)
Balance, June 30, 2019
  
225
   
34,246,714
   
112
   
311,201
   
(280,115
)
  
31,198
 
Retirement of unvested shares
  
-
   
(830,124
)
  
-
   
-
   
-
   
-
 
Common stock awards under equity incentive plans
  
-
   
22,632
   
-
   
282
   
-
   
282
 
Exercise of common stock options
  
-
   
10,000
   
-
   
9
   
-
   
9
 
Retirement of shares received in settlement with the sellers of Golden Ridge
  
-
   
(340,000
)
  
-
   
(1,027
)
  
-
   
(1,027
)
Net loss
  
-
   
-
   
-
   
-
   
(3,326
)
  
(3,326
)
Balance, September  30, 2019
  
225
   
33,109,222
  
$
112
  
$
310,465
  
$
(283,441
)
 
$
27,136
 

On March 30, 2020, we entered into an at market issuance sales agreement with respect to an at-the-market offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million through B. Riley FBR, Inc, as sales agent.  The issuances and sales of our common stock under the agreement are made pursuant to our effective “shelf” registration statement on Form S-3.  During the three months ended September 30, 2020, we issued and sold 1,635,792 shares of common stock under the agreement, at an average price of $0.50 per share.  Proceeds from those sales are recorded in equity, net of $0.2 million of stock issuance costs.  Stock issuance costs consisted of $0.1 million of legal, advisor and auditor expenses paid in the three months ended March 31, 2020, and $0.1 million of other costs related to the offering paid in the three months ended September 30, 2020.

Share-based compensation by type of award follows (in thousands).

  
Three Months Ended
    
  
Sept. 30, 2020
  
June 30, 2020
  
March 31, 2020
 
Common stock, vested and nonvested at issuance
 
$
78
  
$
95
  
$
105
 
Stock options
  
(86
)
  
99
   
85
 
Restricted stock units
  
161
   
122
   
122
 
Compensation expense related to common stock awards issued under equity incentive plan
 $
153
  $
316
  $
312
 

In the three months ended March 31, 2020, we issued 17,534 shares of common stock, vested at issuance, to a consultant at a grant date fair value of $1.11 per share and recognized $0.1 million of expense for shares of common stock vesting during the period.

In the three months ended June 30, 2020, under the equity incentive plan, we (i) issued 16,500 shares of common stock, vested at June 30, 2020, at a grant date fair value or $1.16 per shares and (ii) recognized $0.1 million of expense for shares of common stock vesting during the period.  In the three months ended June 30, 2020, we issued 31,304 shares of common stock to a vendor, vested at June 30, 2020, at a grant date fair value or $1.14 per share.

In the three months ended September 30 2020, we issued (i) 42,383 shares of common stock, vested at issuance, to a consultant at an average grant date fair value of $0.53 per share, (ii) 32,510 shares of common stock, vested at issuance, to a director for board compensation at an average grant date fair value of $0.45 per share, and (iii) 54,511 shares of common stock, vested at issuance, to our former chief executive officer for employment compensation and severance at an average grant date fair value of $0.76 per share,

As of September 30, 2020, there were no shares of nonvested common stock outstanding.

Stock option activity for the nine months ended September 30, 2020, follows.

  
Shares
Under
Options
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Grant
Date Fair
Value
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
Outstanding at December 31, 2019
  
996,009
  
$
3.23
      
8.1
 
Granted
  
653,004
   
1.22
  
$
0.73
   
10.0
 
Forfeited
  
(125,173
)
  
4.74
       
7.2
 
Outstanding at March 31, 2020
  
1,523,840
   
2.24
       
8.8
 
Forfeited
  
(77,357
)
  
4.28
       
7.2
 
Outstanding at June 30, 2020
  
1,446,483
  
$
2.13
       
8.6
 
Forfeited
  
(654,334
)
  
1.97
       
8.8
 
Outstanding at September 30, 2020
  
792,149
  
$
2.27
       
8.1
 

Stock options granted in the three months ended March 31, 2020, each vest and become exercisable in annual installments ending four years from the date of grant and were valued using methods and assumptions comparable to those for our 2019 stock option grants.

Restricted stock unit (RSU) activity for the nine months ended September 30, 2020, follows.

  
RSU Shares
Issued to
Employees
and
Directors
  
Unrecognized
Stock
Compensation
(in thousands)
  
Weighted
Average
Expense
Period
(Years)
 
Nonvested at December 31, 2019
  
1,148,062
  
$
377
   
1.4
 
Cancelled
  
(625,000
)
  
-
     
Forfeited (1)
  
(175,000
)
  
(142
)
    
Expensed (2)
  
-
   
(122
)
    
Nonvested at March 31, 2020
  
348,062
   
113
   
1.2
 
Granted to directors (3)
  
477,018
   
426
     
Forfeited (1)
  
(30,000
)
  
(24
)
    
Vested (4)
  
(115,904
)
  
-
     
Expensed
  
-
   
(122
)
    
Nonvested at June 30, 2020
  
679,176
   
393
   
0.8
 
Granted to directors (3)
  
189,284
   
87
     
Granted to consultant (3)
  
89,286
   
38
     
Forfeited (1)
  
(91,000
)
  
(55
)
    
Vested (4)
  
(189,284
)
  
-
     
Expensed
  
-
   
(161
)
    
Nonvested at September 30, 2020 (5)(6)
  
677,462
   
302
   
0.5
 

 
(1)
We reversed $0.2 million of expense recognized in prior periods on forfeited RSU shares in the amounts indicated in the unrecognized stock compensation column.
 
(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares in the three months ended March 31, 2020.
 
(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(4)
Represents shares of common stock subject to RSUs which were vested when granted.
 
(5)
RSUs for a total of 450,400 shares of common stock vest in June 2021 and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(6)
A total of 227,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 22,706 shares on the date the vesting price equals or exceeds $5.00 per share, (ii) 68,119 shares on the date the vesting price equals or exceeds $10.00 per share and (iii) 136,237 shares on the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.

Warrant activity for the nine months ended September 30, 2020, follows.

  
Shares
Under
Warrants
    
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
          
Outstanding, Decembver 31, 2019
  
7,532,280
  
$
1.32
   
1.9
 
Expired
  
(265,000
)
  
5.25
   
-
 
Outstanding, March 31, 2020
  
7,267,280
   
1.18
   
1.7
 
Cash exercised
  
(12,948
)
  
0.96
   
-
 
Cashless exercised (1)
  
(215,740
)
  
0.96
   
-
 
Expired
  
(392,676
)
  
4.60
   
-
 
Outstanding, June 30, 2020
  
6,645,916
  
$
0.98
   
1.7
 
Outstanding, Septemeber 30, 2020 (2)
  
6,645,916
  
$
0.98
   
1.4
 

 
(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
 
(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of September 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.
v3.20.2
INVOLUNTARY CONVERSION OF ASSETS
 9 Months Ended
Sep. 30, 2020
INVOLUNTARY CONVERSION OF ASSETS [Abstract]  
INVOLUNTARY CONVERSION OF ASSETS
NOTE 11. INVOLUNTARY CONVERSION OF ASSETS

In September 2020, we wrote down assets, consisting primarily of a building, machinery and equipment, in the amount of $0.9 million and incurred other costs of $0.1 million as a result of hurricane damage that occurred in August 2020. This event damaged our Lake Charles, Louisiana property, and operations at that facility were shut down in September 2020.  We expect insurance recoveries will cover our asset loss to the extent it exceeds our $0.1 million deductible under our insurance policy.  In September 2020, we received an advance on the insurance settlement of $0.3 million and we accrued a receivable for the additional $0.7 million of expected insurance proceeds related to our asset loss.  The resulting $0.1 million net loss on involuntary conversion of assets is included in selling, general and administrative expenses in our consolidated financial statements.   The insurance proceeds receivable is included in other current assets on our consolidated balance sheets.  The final settlement with the insurer on this matter will likely differ from the total proceeds we estimated as of September 30, 2020.  We accrue estimated insurance proceeds receivable when the proceeds are estimable and probable of collection.  Given the nature of recoveries of lost profits under business interruption insurance we have not accrued insurance proceeds receivable for any potential recoveries of lost profits under our insurance policy.
v3.20.2
INCOME TAXES
 9 Months Ended
Sep. 30, 2020
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 12. INCOME TAXES

Our tax expense for the three and nine months ended September 30, 2020 and 2019, differs from the tax expense computed by applying the U.S. statutory tax rate to net loss from continuing operations before income taxes as no tax benefits were recorded for tax losses generated in the U.S.  As of September 30, 2020, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards.  We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

Based on an analysis of tax positions taken on income tax returns filed, we have determined no material liabilities related to uncertain income tax positions exist.  Although we believe the amounts reflected in our tax returns substantially comply with applicable U.S. federal, state, and foreign tax regulations, the respective taxing authorities may take contrary positions based on their interpretation of the law.  A tax position successfully challenged by a taxing authority could result in an adjustment to our provision or benefit for income taxes in the period in which a final determination is made.

CARES, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds and modifications to the net interest deduction limitations. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment.  Except for the impact of the loan we received under the act, see Note 9, we do not anticipate that the act will have a material impact on our financial position, results of operations or cash flows.
v3.20.2
LOSS PER SHARE (EPS)
 9 Months Ended
Sep. 30, 2020
LOSS PER SHARE (EPS) [Abstract]  
LOSS PER SHARE (EPS)
NOTE 13. LOSS PER SHARE (EPS)

Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends.  Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive.  The dilutive effects of outstanding options, warrants, nonvested shares of common stock and nonvested restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method.  The dilutive effects of the outstanding preferred stock are calculated using the if-converted method.

Below are reconciliations of the numerators and denominators in the EPS computations.

  
Three Months Ended September 30
  
Nine Months Ended September 30
 
  
2020
  
2019
  
2020
  
2019
 
NUMERATOR (in thousands):
            
Basic and diluted - loss from continuing operations
 
$
(2,774
)
 
$
(3,326
)
 
$
(9,756
)
 
$
(9,996
)
                 
DENOMINATOR:
                
Weighted average number of shares of shares of common stock outstanding
  
40,691,824
   
33,057,010
   
40,232,289
   
31,947,087
 
Weighted average number of shares of common stock underlying vested restricted stock units
  
132,457
   
-
   
47,577
   
-
 
Basic EPS - weighted average number of shares outstanding
  
40,824,281
   
33,057,010
   
40,279,866
   
31,947,087
 
Effect of dilutive securities outstanding
  
-
   
-
   
-
   
-
 
Diluted EPS - weighted average number of shares outstanding
  
40,824,281
   
33,057,010
   
40,279,866
   
31,947,087
 

No effects of potentially dilutive securities outstanding during the three and nine months ended September 30, 2020 and 2019, were included in the calculation of diluted EPS for the three and nine months ended September 30, 2020 and 2019, because to do so would be anti-dilutive as a result of our loss from continuing operations.  Potentially dilutive securities outstanding during the periods included our outstanding convertible preferred stock, options, warrants, nonvested restricted stock units and nonvested stock.  Those potentially dilutive securities, further described in Note 10, could potentially dilute EPS in the future.
v3.20.2
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2020
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 14. FAIR VALUE MEASUREMENTS

Derivative financial instruments are carried at fair value, on a recurring basis, in accumulated OCI, and fair value is based on the quoted prices of the financial instruments (Level 1 measurements).  The fair value of cash and cash equivalents, restricted cash, accounts and other receivables, accounts payable, commodities payable and short-term debt approximated their carrying value due to shorter maturities.  As of September 30, 2020, the fair value of our operating lease liabilities was approximately $0.2 million higher than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).  As of September 30, 2020, the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).
v3.20.2
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2020
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 15. COMMITMENTS AND CONTINGENCIES

Employment Contracts and Severance Payments

In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions.  While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions.  No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control.  In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

Legal Matters

From time to time we are involved in litigation incidental to the conduct of our business.  These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations.  When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. Defense costs are expensed as incurred and are included in professional fees.  While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations, except for a contract dispute to be settled between July 2020 and October 2020.   In the three and nine months ended September 30, 2020, we recognized $0.5 million and $0.7 million, respectively, in cost of goods sold related to the resolution of the contract dispute as it relates to contract periods through September 30, 2020.
v3.20.2
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2020
RELATED PARTY TRANSACTIONS [Abstract]  
RELATED PARTY TRANSACTIONS
NOTE 16. RELATED PARTY TRANSACTIONS

Our director, Ari Gendason, is an employee and senior vice president and chief investment officer of Continental Grain Company (CGC).  As of the date of this filing, CGC owns approximately 25.4% of our outstanding common stock.  We have agreed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors.  In March 2019, we issued and sold to CGC 666,667 shares of common stock at a purchase price of $3.00 per share and a prefunded warrant exercisable into 1,003,344 shares of common stock for $2.99 per share, in a private placement.  The prefunded warrant had an exercise price of $0.01 per share and was immediately exercisable; however, we had to obtain approval from our shareholders before CGC could exercise the prefunded warrant to the extent such exercise would result in the holder owning in excess of 19.99% of our common shares outstanding.  CGC exercised the entire prefunded warrant automatically when our shareholders approved the exercise in June 2019. 
v3.20.2
TRANSACTIONS WITH EMPLOYEES
 9 Months Ended
Sep. 30, 2020
TRANSACTIONS WITH EMPLOYEES [Abstract]  
TRANSACTIONS WITH EMPLOYEES
NOTE 17.  TRANSACTIONS WITH EMPLOYEES

During the three months ended March 31, 2019, we paid $1.4 million to entities owned by our former employee, Wayne Wilkison.  As of September 30, 2020, and December 31, 2019, no amounts were owed to these entities. 
v3.20.2
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS
 9 Months Ended
Sep. 30, 2020
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]  
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS
NOTE 18. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS

On July 27, 2020, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we have failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).  Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00.  To regain compliance with this listing rule, the closing bid price of our common stock must be at least $1.00 for 10 consecutive business days.  We have a period of 180 calendar days from the date of notification, or until January 25, 2021, to regain compliance.  If this appears unlikely as January 25, 2021, approaches, we are committed to taking actions that would enable us to regain compliance, including, if necessary, completing a reverse split of our common stock to increase its share price above the $1.00 minimum bid price.
v3.20.2
BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2020
BASIS OF PRESENTATION [Abstract]  
Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements.  The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2019, which included all disclosures required by generally accepted accounting principles.

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business. 
v3.20.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Recent Accounting Guidance
Recent Accounting Guidance

Recent accounting standards not yet adopted

The following discusses the accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice.

In June 2016, the Financial Accounting Standards Board (FASB) issued guidance ASU No. 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method.  The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts.  The guidance, and subsequent guidance related to the topic, is effective for our annual and interim periods beginning in 2023 and must be adopted on a modified retrospective approach through cumulative-effect adjustment to retained earnings as of January 1, 2023.  Based on the nature of our current receivables and our credit loss history, we do not expect the adoption of the guidance to have a significant impact on our results of operations, financial position, or cash flows.
 
Recently adopted accounting standards

In December 2019, the FASB issued guidance ASU No. 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which, among other things, removed an exception in the guidance to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items such as discontinued operations.  We early adopted the guidance effective January 1, 2020.  Adoption of the guidance had no impact on our results of operations, financial position, or cashflows.
Reclassifications
Reclassifications – Certain reclassifications have been made to amounts reported for the prior period to achieve consistent presentation with the current period. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.
Derivative Financial Instruments
Derivative Financial Instruments

In May 2020, we began, from time to time, to use derivative financial instruments to manage a portion of our risks related to commodity prices.  We do not use derivative financial instruments for trading or speculative purposes.  Changes in the fair value of derivative financial instruments are recognized either in cost of goods sold or in shareholders’ equity as a component of other comprehensive income (loss) (OCI), depending on whether the derivative financial instrument is undesignated or qualifies for hedge accounting.  Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges.  Gains and losses on derivatives designated as cash flow hedges, to the extent they are included in the assessment of effectiveness, are recorded in OCI and subsequently reclassified to cost of goods sold to offset the impact of the hedged items when they occur.  In the event it becomes probable the forecasted transaction to which a cash flow hedge relates will not occur, the derivative is terminated and the amount in accumulated OCI is recognized in earnings.  All cash flows related to derivative financial instruments are classified as operating activities in our consolidated statements of cash flows.
v3.20.2
ACQUISITION (Tables)
 9 Months Ended
Sep. 30, 2020
MGI Grain Processing LLC [Member]  
Business Acquisition [Line Items]  
Pro Forma Financial Information
The following table provides unaudited pro forma information for the three months and nine months ended September 30, 2019, as if the MGI acquisition had occurred January 1, 2019.

  
Three Months Ended
September 30, 2019
  
Nine Months Ended
September 30, 2019
 
Revenues (in thousands)
 
$
5,300
  
$
19,083
 
Loss from continuing operations (in thousands)
 
$
(3,326
)
 
$
(9,865
)
Loss per share - continuing operations
 
$
(0.10
)
 
$
(0.31
)
Weighted average number of common shares outstanding - basic and diluted
  
33,057,010
   
31,947,087
 
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES (Tables)
 9 Months Ended
Sep. 30, 2020
ACCOUNTS RECEIVABLE AND REVENUES [Abstract]  
Concentrations of Risk
Our accounts receivable potentially subject us to significant concentrations of credit risk.  Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

  
Customer


 
A


 
B

  
C

  D

% of revenues, three months ended September 30, 2020
  
6
%
  
12
%
  
11
%
  
4
%
% of revenues, three months ended September 30, 2019
  
10
%
  
13
%
  
11
%
  
3
%
                 
% of revenues, nine months ended September 30, 2020
  
11
%
  
10
%
  
5
%
  
3
%
% of revenues, nine months ended September 30, 2019
  
14
%
  
11
%
  
10
%
  
1
%
                 
% of accounts receivable, as of September 30, 2020
  
5
%
  
19
%
  
12
%
  
10
%
% of accounts receivable, as of December 31, 2019
  
31
%
  
10
%
  
8
%
  
10
%
Revenues by Product Line
In all periods presented, less than 10% of our revenues related to shipments to locations outside of the U.S.  The following table presents revenues by product line (in thousands).

  
Three Months Ended September 30
  
Nine Months Ended September 30
 
  
2020
  
2019
  
2020
  
2019
 
Food
 
$
3,160
  
$
3,573
  
$
13,319
  
$
12,685
 
Animal nutrition
  
2,000
   
1,727
   
6,074
   
5,198
 
Revenues
 
$
5,160
  
$
5,300
  
$
19,393
  
$
17,883
 
v3.20.2
INVENTORIES (Tables)
 9 Months Ended
Sep. 30, 2020
INVENTORIES [Abstract]  
Components of Inventories
The following table details the components of inventories (in thousands).

    
September 30,
2020
    
December 31,
2019
  
Finished goods
 
$
1,363
  
$
698
 
Raw materials
  
180
   
90
 
Packaging
  
122
   
110
 
Inventories
 
$
1,665
  
$
898
 
v3.20.2
LEASES (Tables)
 9 Months Ended
Sep. 30, 2020
LEASES [Abstract]  
Components of Lease Expense
The components of lease expense and cash flows from leases (in thousands) follow.

  
Three Months Ended September 30,
  
Nine Months Ended September 30,
 
  
2020
  
2019
  
2020
  
2019
 
Finance lease cost:
            
Amortization of right-of use assets, included in cost of goods sold
 
$
21
  
$
19
  
$
62
  
$
50
 
Interest on lease liabilities
  
3
   
5
   
11
   
10
 
Operating lease cost, included in selling, general and administrative expenses:
                
Fixed leases cost
  
127
   
131
   
388
   
392
 
Variable lease cost
  
41
   
35
   
89
   
99
 
Short-term lease cost
  
-
   
13
   
3
   
29
 
Total lease cost
 
$
192
  
$
203
  
$
553
  
$
580
 
                 
Cash paid for amounts included in the measurement of lease liabilities:
                
Operating cash flows from finance leases
 
$
3
  
$
5
  
$
11
  
$
10
 
Operating cash flows from operating leases
 
$
127
  
$
131
  
$
388
  
$
392
 
Financing cash flows from finance leases
 
$
29
  
$
23
  
$
75
  
$
54
 
Remaining Lease Term and Discount Rate
The remaining terms of our leases and the discount rates used in the calculation of the fair value of our leases as of September 30, 2020, follows.

  
Operating
Leases
  
Finance
Leases
 
Remaining leases terms (in years)
  
3.1-12.4
   
0.3-3.8
 
Weighted average remaining lease terms (in years)
  
7.2
   
2.7
 
Discount rates
  
6.3%-9.0
%
  
4.3%-7.3
%
Weighted average discount rate
  
7.6
%
  
5.9
%
Maturities of Lease Liabilities
Maturities of lease liabilities as of September 30, 2020, follows (in thousands).

    
Operating
Leases
    
Finance
Leases
  
2020 (three months ended December 31, 2020)
 
$
116
  
$
28
 
2021
  
536
   
91
 
2022
  
548
   
68
 
2023
  
528
   
38
 
2024
  
428
   
11
 
Thereafter
  
1,468
   
-
 
Total lease payments
  
3,624
   
236
 
Amounts representing interest
  
(887
)
  
(15
)
Present value of lease obligations
 
$
2,737
  
$
221
 
v3.20.2
DEBT (Tables)
 9 Months Ended
Sep. 30, 2020
DEBT [Abstract]  
Dues Under Factoring Agreement
Due under factoring agreement consists of the following (in thousands).

    
September 30,
2020
    
December 31,
2019
  
Borrowings outstanding
 
$
1,912
  
$
1,989
 
Debt issuance costs, net
  
(98
)
  
(166
)
Due under factoring agreement
 
$
1,814
  
$
1,823
 
Long-term Debt
Long-term debt consists of the following (in thousands).

   
September 30,
2020
  
December 31,
2019
 
Payroll Protection Program note - Dated April 2020.  Interest accrues at an annual rate of 1.0%.
      
Due in monthly installments from November 2020 to April 2022, unless forgiven as described below.
 
$
1,792
  
$
-
 
Mortgage promissory note - Dated September 2020.  Interest accrues at an annual rate which is the greater of 11.0% above the lender's prime rate and 14.3%.  Payable in monthly installments through June 2022.
  
985
   
-
 
Debt issuance costs, net - Related to mortgage promissory note dated September 2020
  
(15
)
  
-
 
Equipment notes - Initially recorded in November 2018, in the acquisition of Golden Ridge, at the present value of future payments using a discount rate of 4.8% per year, which we determined approximated the market rate for similar debt with similar maturities as of the date of acquisition.  Payable in monthly installments.
Expire at dates ranging through 2022.
  
43
   
62
 
Equipment note - Dated December 2019.  Due in monthly installments through December 2024.
        
Interest accrues at the effective discount rate of 9.3% per year.
  
34
   
39
 
Total long term debt, net
 
$
2,839
  
$
101
 
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)
 9 Months Ended
Sep. 30, 2020
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]  
Equity Activity
A summary of equity activity follows (in thousands, except share amounts).

  
Shares
        

  
Accumulated Other
     
    
Preferred
Series G
      
Common
    
Preferred
Stock
    
Common
Stock
    
Accumulated
Deficit
    
Comprehensive
Loss
     
Equity
  
Balance, December 31, 2019
  
225
   
40,074,483
  
$
112
  
$
318,811
  
$
(287,180
)
 
$
-
  
$
31,743
 
Common stock awards under equity incentive plans
  
-
   
17,534
   
-
   
312
   
-
   
-
   
312
 
Net loss
  
-
   
-
   
-
   
-
   
(3,033
)
  
-
   
(3,033
)
Balance, March 31, 2020
  
225
   
40,092,017
   
112
   
319,123
   
(290,213
)
  
-
   
29,022
 
Common stock awards under equity incentive plans
  
-
   
16,500
   
-
   
316
   
-
   
-
   
316
 
Common stock issued to vendors
  
-
   
31,304
   
-
   
36
   
-
   
-
   
36
 
Exercise of common stock warrants
  
-
   
67,577
   
-
   
12
   
-
   
-
   
12
 
Other comprehensive loss
  
-
   
-
   
-
   
-
   
-
   
(48
)
  
(48
)
Net loss
  
-
   
-
   
-
   
-
   
(3,949
)
  
-
   
(3,949
)
Balance, June 30, 2020
  
225
   
40,207,398
   
112
   
319,487
   
(294,162
)
  
(48
)
  
25,389
 
Common stock awards under equity incentive plans
  
-
   
129,404
   
-
   
153
   
-
   
-
   
153
 
Sale of common stock, net of costs
  
-
   
1,635,792
   
-
   
657
   
-
   
-
   
657
 
Other comprehensive income
  
-
   
-
   
-
   
-
   
-
   
48
   
48
 
Net loss
  
-
   
-
   
-
   
-
   
(2,774
)
  
-
   
(2,774
)
Balance, September  30, 2020
  
225
   
41,972,594
  
$
112
  
$
320,297
  
$
(296,936
)
 
$
-
  
$
23,473
 

  
Shares
          
   
Preferred
Series G
  
Common
  
Preferred
Stock
  
Common
Stock
  
Accumulated
Deficit
  
Equity
 
Balance, December 31, 2018
  
405
   
29,098,207
  
$
201
  
$
296,739
  
$
(273,229
)
 
$
23,711
 
Sale of common stock and Prefunded Warrant, net of costs
  
-
   
3,046,668
   
-
   
11,593
   
-
   
11,593
 
Common stock awards under equity incentive plans
  
-
   
36,881
   
-
   
364
   
-
   
364
 
Exercise of common stock warrants
  
-
   
600,000
   
-
   
1,980
   
-
   
1,980
 
Conversion of preferred stock into common stock
  
(180
)
  
170,818
   
(89
)
  
89
   
-
   
-
 
Exercise of common stock options
  
-
   
77,078
   
-
   
60
   
-
   
60
 
Other
  
-
   
-
   
-
   
28
   
-
   
28
 
Net loss
  
-
   
-
   
-
   
-
   
(3,227
)
  
(3,227
)
Balance, March 31, 2019
  
225
   
33,029,652
   
112
   
310,853
   
(276,456
)
  
34,509
 
Exercise of Prefunded Warrant
  
-
   
1,003,344
   
-
   
10
   
-
   
10
 
Common stock awards under equity incentive plans
  
-
   
134,984
   
-
   
219
   
-
   
219
 
Exercise of common stock options
  
-
   
78,734
   
-
   
87
   
-
   
87
 
Other
  
-
   
-
   
-
   
32
   
-
   
32
 
Net loss
  
-
   
-
   
-
   
-
   
(3,659
)
  
(3,659
)
Balance, June 30, 2019
  
225
   
34,246,714
   
112
   
311,201
   
(280,115
)
  
31,198
 
Retirement of unvested shares
  
-
   
(830,124
)
  
-
   
-
   
-
   
-
 
Common stock awards under equity incentive plans
  
-
   
22,632
   
-
   
282
   
-
   
282
 
Exercise of common stock options
  
-
   
10,000
   
-
   
9
   
-
   
9
 
Retirement of shares received in settlement with the sellers of Golden Ridge
  
-
   
(340,000
)
  
-
   
(1,027
)
  
-
   
(1,027
)
Net loss
  
-
   
-
   
-
   
-
   
(3,326
)
  
(3,326
)
Balance, September  30, 2019
  
225
   
33,109,222
  
$
112
  
$
310,465
  
$
(283,441
)
 
$
27,136
 
Share-based Compensation by Type of Award
Share-based compensation by type of award follows (in thousands).

  
Three Months Ended
    
  
Sept. 30, 2020
  
June 30, 2020
  
March 31, 2020
 
Common stock, vested and nonvested at issuance
 
$
78
  
$
95
  
$
105
 
Stock options
  
(86
)
  
99
   
85
 
Restricted stock units
  
161
   
122
   
122
 
Compensation expense related to common stock awards issued under equity incentive plan
 $
153
  $
316
  $
312
 
Stock Option Activity
Stock option activity for the nine months ended September 30, 2020, follows.

  
Shares
Under
Options
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Grant
Date Fair
Value
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
Outstanding at December 31, 2019
  
996,009
  
$
3.23
      
8.1
 
Granted
  
653,004
   
1.22
  
$
0.73
   
10.0
 
Forfeited
  
(125,173
)
  
4.74
       
7.2
 
Outstanding at March 31, 2020
  
1,523,840
   
2.24
       
8.8
 
Forfeited
  
(77,357
)
  
4.28
       
7.2
 
Outstanding at June 30, 2020
  
1,446,483
  
$
2.13
       
8.6
 
Forfeited
  
(654,334
)
  
1.97
       
8.8
 
Outstanding at September 30, 2020
  
792,149
  
$
2.27
       
8.1
 
RSU Activity
Restricted stock unit (RSU) activity for the nine months ended September 30, 2020, follows.

  
RSU Shares
Issued to
Employees
and
Directors
  
Unrecognized
Stock
Compensation
(in thousands)
  
Weighted
Average
Expense
Period
(Years)
 
Nonvested at December 31, 2019
  
1,148,062
  
$
377
   
1.4
 
Cancelled
  
(625,000
)
  
-
     
Forfeited (1)
  
(175,000
)
  
(142
)
    
Expensed (2)
  
-
   
(122
)
    
Nonvested at March 31, 2020
  
348,062
   
113
   
1.2
 
Granted to directors (3)
  
477,018
   
426
     
Forfeited (1)
  
(30,000
)
  
(24
)
    
Vested (4)
  
(115,904
)
  
-
     
Expensed
  
-
   
(122
)
    
Nonvested at June 30, 2020
  
679,176
   
393
   
0.8
 
Granted to directors (3)
  
189,284
   
87
     
Granted to consultant (3)
  
89,286
   
38
     
Forfeited (1)
  
(91,000
)
  
(55
)
    
Vested (4)
  
(189,284
)
  
-
     
Expensed
  
-
   
(161
)
    
Nonvested at September 30, 2020 (5)(6)
  
677,462
   
302
   
0.5
 

 
(1)
We reversed $0.2 million of expense recognized in prior periods on forfeited RSU shares in the amounts indicated in the unrecognized stock compensation column.
 
(2)
We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares in the three months ended March 31, 2020.
 
(3)
The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(4)
Represents shares of common stock subject to RSUs which were vested when granted.
 
(5)
RSUs for a total of 450,400 shares of common stock vest in June 2021 and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.
 
(6)
A total of 227,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days.  Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 22,706 shares on the date the vesting price equals or exceeds $5.00 per share, (ii) 68,119 shares on the date the vesting price equals or exceeds $10.00 per share and (iii) 136,237 shares on the date the vesting price equals or exceeds $15.00 per share.  Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence.  The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
Warrant Activity
Warrant activity for the nine months ended September 30, 2020, follows.

  
Shares
Under
Warrants
    
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
Life (Years)
 
          
Outstanding, Decembver 31, 2019
  
7,532,280
  
$
1.32
   
1.9
 
Expired
  
(265,000
)
  
5.25
   
-
 
Outstanding, March 31, 2020
  
7,267,280
   
1.18
   
1.7
 
Cash exercised
  
(12,948
)
  
0.96
   
-
 
Cashless exercised (1)
  
(215,740
)
  
0.96
   
-
 
Expired
  
(392,676
)
  
4.60
   
-
 
Outstanding, June 30, 2020
  
6,645,916
  
$
0.98
   
1.7
 
Outstanding, Septemeber 30, 2020 (2)
  
6,645,916
  
$
0.98
   
1.4
 

 
(1)
In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
 
(2)
Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature.  As of September 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an exercise price of $5.25 per share.  If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise.  If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature.
v3.20.2
LOSS PER SHARE (EPS) (Tables)
 9 Months Ended
Sep. 30, 2020
LOSS PER SHARE (EPS) [Abstract]  
Reconciliations of Numerators and Denominators in EPS Computations
Below are reconciliations of the numerators and denominators in the EPS computations.

  
Three Months Ended September 30
  
Nine Months Ended September 30
 
  
2020
  
2019
  
2020
  
2019
 
NUMERATOR (in thousands):
            
Basic and diluted - loss from continuing operations
 
$
(2,774
)
 
$
(3,326
)
 
$
(9,756
)
 
$
(9,996
)
                 
DENOMINATOR:
                
Weighted average number of shares of shares of common stock outstanding
  
40,691,824
   
33,057,010
   
40,232,289
   
31,947,087
 
Weighted average number of shares of common stock underlying vested restricted stock units
  
132,457
   
-
   
47,577
   
-
 
Basic EPS - weighted average number of shares outstanding
  
40,824,281
   
33,057,010
   
40,279,866
   
31,947,087
 
Effect of dilutive securities outstanding
  
-
   
-
   
-
   
-
 
Diluted EPS - weighted average number of shares outstanding
  
40,824,281
   
33,057,010
   
40,279,866
   
31,947,087
 
v3.20.2
BUSINESS (Details)
Sep. 30, 2020
Location
BUSINESS [Abstract]  
Number of locations 4
Number of locations in California 2
Number of locations in Louisiana 1
v3.20.2
ACQUISITION (Details) - MGI Grain Processing LLC [Member] - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Business Acquisition, Pro Forma Information [Abstract]    
Revenues $ 5,300 $ 19,083
Loss from continuing operations $ (3,326) $ (9,865)
Loss per share - continuing operations (in dollars per share) $ (0.10) $ (0.31)
Weighted average number of common shares outstanding - basic and diluted (in shares) 33,057,010 31,947,087
v3.20.2
CASH AND CASH EQUIVALENTS (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 3,890 $ 8,444 $ 3,690 $ 7,044
Money Market Funds [Member]        
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 2,400      
v3.20.2
ACCOUNTS RECEIVABLE AND REVENUES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Concentration of Credit Risk [Abstract]          
Revenues $ 5,160 $ 5,300 $ 19,393 $ 17,883  
Revenue unearned 0   $ 0   $ 12
Minimum [Member]          
Concentration of Credit Risk [Abstract]          
Receivables payment term     30 days    
Maximum [Member]          
Concentration of Credit Risk [Abstract]          
Receivables payment term     120 days    
Revenue unearned 100   $ 100    
Operating Segments [Member] | Food [Member]          
Concentration of Credit Risk [Abstract]          
Revenues 3,160 3,573 13,319 12,685  
Operating Segments [Member] | Animal Nutrition [Member]          
Concentration of Credit Risk [Abstract]          
Revenues $ 2,000 $ 1,727 $ 6,074 $ 5,198  
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 6.00% 10.00% 11.00% 14.00%  
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     5.00%   31.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 12.00% 13.00% 10.00% 11.00%  
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     19.00%   10.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 11.00% 11.00% 5.00% 10.00%  
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     12.00%   8.00%
Customer D [Member] | Revenue [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage 4.00% 3.00% 3.00% 1.00%  
Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]          
Concentration of Credit Risk [Abstract]          
Concentration risk, percentage     10.00%   10.00%
v3.20.2
INVENTORIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Inventories [Abstract]    
Finished goods $ 1,363 $ 698
Raw materials 180 90
Packaging 122 110
Inventories $ 1,665 $ 898
v3.20.2
LEASES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Finance lease cost [Abstract]        
Amortization of right-of use assets, included in cost of goods sold $ 21 $ 19 $ 62 $ 50
Interest on lease liabilities 3 5 11 10
Operating lease cost, included in selling, general and administrative expenses [Abstract]        
Fixed leases cost 127 131 388 392
Variable lease cost 41 35 89 99
Short-term lease cost 0 13 3 29
Total lease cost 192 203 553 580
Cash paid for amounts included in the measurement of lease liabilities [Abstract]        
Operating cash flows from finance leases 3 5 11 10
Operating cash flows from operating leases 127 131 388 392
Financing cash flows from finance leases 29 $ 23 75 $ 54
Finance lease right-of-use-assets, net $ 300   $ 300  
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] us-gaap:PropertyPlantAndEquipmentNet   us-gaap:PropertyPlantAndEquipmentNet  
Finance lease right-of-use-assets, original cost $ 400   $ 400  
Operating Leases [Abstract]        
Weighted average remaining lease terms (in years) 7 years 2 months 12 days   7 years 2 months 12 days  
Weighted average discount rate 7.60%   7.60%  
Finance Leases [Abstract]        
Weighted average remaining lease terms (in years) 2 years 8 months 12 days   2 years 8 months 12 days  
Weighted average discount rate 5.90%   5.90%  
Maturities of Operating Lease Liabilities [Abstract]        
2020 (six months ended December 31, 2020) $ 116   $ 116  
2021 536   536  
2022 548   548  
2023 528   528  
2024 428   428  
Thereafter 1,468   1,468  
Total lease payments 3,624   3,624  
Amounts representing interest (887)   (887)  
Present value of lease obligations 2,737   2,737  
Maturities of Finance Lease Liabilities [Abstract]        
2020 (six months ended December 31, 2020) 28   28  
2021 91   91  
2022 68   68  
2023 38   38  
2024 11   11  
Thereafter 0   0  
Total lease payments 236   236  
Amounts representing interest (15)   (15)  
Present value of lease obligations $ 221   $ 221  
Minimum [Member]        
Operating Leases [Abstract]        
Remaining leases terms (in years)     3 years 1 month 6 days  
Discount rate 6.30%   6.30%  
Finance Leases [Abstract]        
Remaining leases terms (in years)     3 months 18 days  
Discount rate 4.30%   4.30%  
Maximum [Member]        
Operating Leases [Abstract]        
Remaining leases terms (in years)     12 years 4 months 24 days  
Discount rate 9.00%   9.00%  
Finance Leases [Abstract]        
Remaining leases terms (in years)     3 years 9 months 18 days  
Discount rate 7.30%   7.30%  
v3.20.2
DEBT (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2019
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Oct. 31, 2020
Dec. 31, 2019
Due under Factoring Agreement [Abstract]            
Due under factoring agreement   $ 1,814 $ 1,814     $ 1,823
Long-term Debt [Abstract]            
Total long term debt, net   $ 2,839 $ 2,839     101
Minimum [Member]            
Debt Instruments [Abstract]            
Interest rate   4.70% 4.70%      
Maximum [Member]            
Debt Instruments [Abstract]            
Interest rate   5.50% 5.50%      
Factoring Agreement [Member]            
Due under Factoring Agreement [Abstract]            
Borrowing outstanding   $ 1,912 $ 1,912     1,989
Debt issuance costs, net   (98) (98)     (166)
Due under factoring agreement   1,814 1,814     1,823
Long-term Debt [Abstract]            
Debt issuance costs, net   $ (98) $ (98)     (166)
Factoring Agreement [Member] | Line of Credit [Member]            
Debt Instruments [Abstract]            
Line of credit facility, maximum borrowing capacity $ 7,000          
Line of credit facility, initial term     2 years      
Facility fee, amount $ 200          
Percentage of funding fee   0.50% 0.50%      
Outstanding borrowings average amount   $ 1,700 $ 1,900      
Interest and fees expense     $ 200      
Fees incurred average percentage   5.60% 7.90%      
Average interest percentage   6.00% 6.30%      
Amortization of debt issuance costs     $ 100      
Factoring Agreement [Member] | Line of Credit [Member] | Minimum [Member]            
Debt Instruments [Abstract]            
Line of credit facility, recurring fee 5.50%          
Factoring Agreement [Member] | Line of Credit [Member] | Maximum [Member]            
Debt Instruments [Abstract]            
Interest and fees expense   $ 100        
Paycheck Protection Program [Member] | Notes Payable [Member]            
Debt Instruments [Abstract]            
Interest rate   1.00% 1.00%      
Long-term Debt [Abstract]            
Total long term debt, net   $ 1,792 $ 1,792     0
Maturity date of note start     Nov. 30, 2020      
Maturity date of note end     Apr. 30, 2022      
Mortgage Agreement [Member]            
Debt Instruments [Abstract]            
Interest rate   14.30% 14.30%      
Long-term Debt [Abstract]            
Maturity date     Jun. 30, 2022      
Credit facility fee percentage on amount of each advance       1.00%    
Mortgage Agreement [Member] | Subsequent Event [Member]            
Long-term Debt [Abstract]            
Line of credit facility, remaining borrowing capacity         $ 1,000  
Mortgage Agreement [Member] | Minimum [Member] | Prime Rate [Member]            
Long-term Debt [Abstract]            
Accrued interest on borrowings at annual rate       11.00%    
Mortgage Agreement [Member] | Notes Payable [Member]            
Due under Factoring Agreement [Abstract]            
Debt issuance costs, net   $ (15) $ (15)     0
Long-term Debt [Abstract]            
Total long term debt, net   985 985     0
Debt issuance costs, net   $ (15) $ (15)     0
Equipment Notes, November 2018 [Member] | Notes Payable [Member]            
Debt Instruments [Abstract]            
Interest rate   4.80% 4.80%      
Long-term Debt [Abstract]            
Total long term debt, net   $ 43 $ 43     62
Maturity date     Dec. 31, 2022      
Equipment Notes, December 2019 [Member] | Notes Payable [Member]            
Debt Instruments [Abstract]            
Interest rate   9.30% 9.30%      
Long-term Debt [Abstract]            
Total long term debt, net   $ 34 $ 34     $ 39
Maturity date     Dec. 31, 2024      
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Summary of Equity Activity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
May 31, 2020
Dec. 31, 2019
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]                    
Common stock, shares authorized (in shares) 150,000,000 150,000,000         150,000,000   50,000,000 150,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance $ 25,389 $ 29,022 $ 31,743 $ 31,198 $ 34,509 $ 23,711 $ 31,743 $ 23,711    
Balance (in shares)     40,074,483       40,074,483      
Sale of common stock and Prefunded Warrant, net of costs 657         11,593        
Exercise of Prefunded Warrant         10          
Retirement of unvested shares       0            
Common stock awards under equity incentive plans 153 316 $ 312 282 219 364        
Common stock issued to vendors   36                
Exercise of common stock warrants   12       1,980        
Conversion of preferred stock into common stock           0        
Exercise of common stock options       9 87 60        
Sale of common stock, net of costs 657         11,593        
Other         32 28        
Other comprehensive income (loss) 48 (48)   0     $ 0 0    
Retirement of shares received in settlement with the sellers of Golden Ridge       (1,027)            
Net loss (2,774) (3,949) (3,033) (3,326) (3,659) (3,227) (9,756) (10,212)    
Balance $ 23,473 25,389 29,022 27,136 31,198 34,509 $ 23,473 27,136    
Balance (in shares) 41,972,594           41,972,594      
Preferred Stock [Member]                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance $ 112 112 112 112 112 201 $ 112 201    
Sale of common stock and Prefunded Warrant, net of costs 0         0        
Exercise of Prefunded Warrant         0          
Retirement of unvested shares       0            
Common stock awards under equity incentive plans 0 0 0 0 0 0        
Common stock issued to vendors   0                
Exercise of common stock warrants   0       0        
Conversion of preferred stock into common stock           (89)        
Exercise of common stock options       0 0 0        
Sale of common stock, net of costs 0         0        
Other         0 0        
Other comprehensive income (loss) 0 0                
Retirement of shares received in settlement with the sellers of Golden Ridge       0            
Net loss 0 0 0 0 0 0        
Balance $ 112 $ 112 $ 112 $ 112 $ 112 $ 112 $ 112 $ 112    
Preferred Stock [Member] | Series G Preferred Stock [Member]                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance (in shares) 225 225 225 225 225 405 225 405    
Sale of common stock and Prefunded Warrant, net of costs (in shares) 0         0        
Exercise of Prefunded Warrant (in shares)         0          
Retirement of unvested shares (in shares)       0            
Common stock awards under equity incentive plans (in shares) 0 0 0 0 0 0        
Common stock issued to vendors (in shares)   0                
Exercise of common stock warrants (in shares)   0       0        
Conversion of preferred stock into common stock (in shares)           (180)        
Exercise of common stock options (in shares)       0 0 0        
Sale of common stock (in shares) 0         0        
Other (in shares)         0 0        
Retirement of shares received in settlement with the sellers of Golden Ridge (in shares)       0            
Balance (in shares) 225 225 225 225 225 225 225 225    
Common Stock [Member]                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance $ 319,487 $ 319,123 $ 318,811 $ 311,201 $ 310,853 $ 296,739 $ 318,811 $ 296,739    
Balance (in shares) 40,207,398 40,092,017 40,074,483 34,246,714 33,029,652 29,098,207 40,074,483 29,098,207    
Sale of common stock and Prefunded Warrant, net of costs $ 657         $ 11,593        
Sale of common stock and Prefunded Warrant, net of costs (in shares) 1,635,792         3,046,668        
Exercise of Prefunded Warrant         $ 10          
Exercise of Prefunded Warrant (in shares)         1,003,344          
Retirement of unvested shares       $ 0            
Retirement of unvested shares (in shares)       (830,124)            
Common stock awards under equity incentive plans $ 153 $ 316 $ 312 $ 282 $ 219 $ 364        
Common stock awards under equity incentive plans (in shares) 129,404 16,500 17,534 22,632 134,984 36,881        
Common stock issued to vendors   $ 36                
Common stock issued to vendors (in shares)   31,304                
Exercise of common stock warrants   $ 12       $ 1,980        
Exercise of common stock warrants (in shares)   67,577       600,000        
Conversion of preferred stock into common stock           $ 89        
Conversion of preferred stock into common stock (in shares)           170,818        
Exercise of common stock options       $ 9 $ 87 $ 60        
Exercise of common stock options (in shares)       10,000 78,734 77,078        
Sale of common stock, net of costs $ 657         $ 11,593        
Sale of common stock (in shares) 1,635,792         3,046,668        
Other         $ 32 $ 28        
Other (in shares)         0 0        
Other comprehensive income (loss) $ 0 $ 0                
Retirement of shares received in settlement with the sellers of Golden Ridge       $ (1,027)            
Retirement of shares received in settlement with the sellers of Golden Ridge (in shares)       (340,000)            
Net loss 0 0 $ 0 $ 0 $ 0 $ 0        
Balance $ 320,297 $ 319,487 $ 319,123 $ 310,465 $ 311,201 $ 310,853 $ 320,297 $ 310,465    
Balance (in shares) 41,972,594 40,207,398 40,092,017 33,109,222 34,246,714 33,029,652 41,972,594 33,109,222    
Accumulated Deficit [Member]                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance $ (294,162) $ (290,213) $ (287,180) $ (280,115) $ (276,456) $ (273,229) $ (287,180) $ (273,229)    
Sale of common stock and Prefunded Warrant, net of costs 0         0        
Exercise of Prefunded Warrant         0          
Retirement of unvested shares       0            
Common stock awards under equity incentive plans 0 0 0 0 0 0        
Common stock issued to vendors   0                
Exercise of common stock warrants   0       0        
Conversion of preferred stock into common stock           0        
Exercise of common stock options       0 0 0        
Sale of common stock, net of costs 0         0        
Other         0 0        
Other comprehensive income (loss) 0 0                
Retirement of shares received in settlement with the sellers of Golden Ridge       0            
Net loss (2,774) (3,949) (3,033) (3,326) (3,659) (3,227)        
Balance (296,936) (294,162) (290,213) $ (283,441) $ (280,115) $ (276,456) (296,936) $ (283,441)    
Accumulated Other Comprehensive Loss [Member]                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Balance (48) 0 0       0      
Sale of common stock and Prefunded Warrant, net of costs 0                  
Common stock awards under equity incentive plans 0 0 0              
Common stock issued to vendors   0                
Exercise of common stock warrants   0                
Sale of common stock, net of costs 0                  
Other comprehensive income (loss) 48 (48)                
Net loss 0 0 0              
Balance $ 0 $ (48) $ 0       $ 0      
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Sales Agreement (Details) - At-the-Market Offering [Member] - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Mar. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]      
Sale of common stock (in shares) 1,635,792    
Common stock, average price (in dollars per share) $ 0.50    
Stock issuance costs $ 0.2    
Payment for legal, advisor and auditor expenses   $ 0.1  
Other stock issuance costs $ 0.1    
Maximum [Member]      
Share Based Compensation Arrangement By Share Based Payment Award Information [Abstract]      
Aggregate offering price of common stock     $ 6.0
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Share-Based Compensation by Type of Award (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan $ 153 $ 316 $ 312      
Common Stock [Member]            
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan   $ 100        
Common Stock Issued under Equity Incentive Plans [Abstract]            
Shares issued (in shares) 129,404 16,500 17,534 22,632 134,984 36,881
Grant date fair value (in dollars per share)   $ 1.16        
Nonvested common stock outstanding (in shares) 0          
Common Stock [Member] | Director [Member]            
Common Stock Issued under Equity Incentive Plans [Abstract]            
Shares issued (in shares) 32,510          
Grant date fair value (in dollars per share) $ 0.45          
Common Stock [Member] | Chief Executive Officer [Member]            
Common Stock Issued under Equity Incentive Plans [Abstract]            
Shares issued (in shares) 54,511          
Grant date fair value (in dollars per share) $ 0.76          
Common Stock [Member] | Consultant [Member]            
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan     $ 100      
Common Stock Issued under Equity Incentive Plans [Abstract]            
Shares issued (in shares) 42,383   17,534      
Grant date fair value (in dollars per share) $ 0.53   $ 1.11      
Common Stock [Member] | Vendor [Member]            
Common Stock Issued under Equity Incentive Plans [Abstract]            
Shares issued (in shares)   31,304        
Grant date fair value (in dollars per share)   $ 1.14        
Common Stock, Vested and Nonvested at Issuance [Member]            
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan $ 78 $ 95 $ 105      
Stock Options [Member]            
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan (86) 99 85      
Restricted Stock Units [Member]            
Share-based compensation expense [Abstract]            
Compensation expense related to common stock awards issued under equity incentive plan $ 161 $ 122 $ 122      
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Stock Options (Details) - Stock Options [Member] - $ / shares
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Shares Under Options, Outstanding [Roll Forward]          
Outstanding at beginning of period (in shares) 1,446,483 1,523,840 996,009 996,009  
Granted (in shares)     653,004    
Forfeited (in shares) (654,334) (77,357) (125,173)    
Outstanding at end of period (in shares) 792,149 1,446,483 1,523,840 792,149 996,009
Options, Weighted Average Exercise Price [Roll Forward]          
Outstanding at beginning of period (in dollars per share) $ 2.13 $ 2.24 $ 3.23 $ 3.23  
Granted (in dollars per share)     1.22    
Forfeited (in dollars per share) 1.97 4.28 4.74    
Outstanding at end of period (in dollars per share) $ 2.27 $ 2.13 2.24 $ 2.27 $ 3.23
Options, Weighted Average Grant Date Fair Value [Abstract]          
Granted (in dollars per share)     $ 0.73    
Options, Weighted Average Remaining Contractual Life [Abstract]          
Outstanding, weighted average remaining contractual life 8 years 1 month 6 days 8 years 7 months 6 days 8 years 9 months 18 days   8 years 1 month 6 days
Granted     10 years    
Forfeited 8 years 9 months 18 days 7 years 2 months 12 days 7 years 2 months 12 days    
Options exercisable period       4 years  
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Restricted Stock Units (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2020
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Share-based compensation expense recognized $ 153 $ 316 $ 312      
Restricted Stock Units [Member]            
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Share-based compensation expense reversal on forfeited shares 200 200 200      
Share-based compensation expense recognized $ 161 $ 122 $ 122      
Restricted Stock Units [Member] | Minimum [Member]            
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Award vesting period 1 year          
Restricted Stock Units [Member] | Maximum [Member]            
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Award vesting period 5 years          
Restricted Stock Units [Member] | Consultant [Member] | Maximum [Member]            
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Award vesting period 1 year          
Restricted Stock Units [Member] | Employee and Director [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Beginning balance, Nonvested (in shares) 679,176 348,062 1,148,062 1,148,062    
Granted (in shares) [1] 189,284 477,018        
Cancelled (in shares)     (625,000)      
Forfeited (in shares) [2] (91,000) (30,000) (175,000)      
Vested (in shares) [3] (189,284) (115,904)        
Ending balance, Nonvested (in shares) 677,462 [4],[5] 679,176 348,062 677,462 [4],[5] 1,148,062  
Unrecognized Stock Compensation [Abstract]            
Unrecognized stock compensation $ 393 $ 113 $ 377 $ 377    
Granted [1] 87 426        
Cancelled     0      
Vested [3] 0 0        
Expensed (161) (122) (122) [6]      
Forfeited [2] (55) (24) (142)      
Unrecognized stock compensation $ 302 [4],[5] $ 393 $ 113 $ 302 [4],[5] $ 377  
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Weighted average expense period (Years) 6 months [4],[5] 9 months 18 days 1 year 2 months 12 days   1 year 4 months 24 days  
Nonvested shares (in shares) 677,462 [4],[5] 348,062 348,062 677,462 [4],[5] 1,148,062 677,462 [4],[5]
Restricted Stock Units [Member] | Employee and Director [Member] | Consultant [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Granted (in shares) [1] 89,286          
Unrecognized Stock Compensation [Abstract]            
Granted [1] $ 38          
Restricted Stock Units [Member] | Director [Member] | Maximum [Member]            
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Award vesting period 1 year 1 year        
Vesting June 2021 [Member] | Restricted Stock Units [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Ending balance, Nonvested (in shares) 450,400     450,400    
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Nonvested shares (in shares) 450,400     450,400   450,400
Vesting Price Equal to Volume Weighted Average Trading Price of Common Stock [Member] | Restricted Stock Units [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Ending balance, Nonvested (in shares) 227,062     227,062    
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Number of trading days       65 days    
Nonvested shares (in shares) 227,062     227,062   227,062
Vesting Price Equals or Exceeds $5.00 [Member] | Restricted Stock Units [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Ending balance, Nonvested (in shares) 22,706     22,706    
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Nonvested shares (in shares) 22,706     22,706   22,706
Vesting price (in dollars per share)           $ 5.00
Vesting Price Equals or Exceeds $10.00 [Member] | Restricted Stock Units [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Ending balance, Nonvested (in shares) 68,119     68,119    
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Nonvested shares (in shares) 68,119     68,119   68,119
Vesting price (in dollars per share)           $ 10.00
Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member]            
Restricted Stock Award Activity, Number [Roll Forward]            
Ending balance, Nonvested (in shares) 136,237     136,237    
Weighted Average Remaining Vesting and Expense Period [Abstract]            
Nonvested shares (in shares) 136,237     136,237   136,237
Vesting price (in dollars per share)           $ 15.00
[1] The shares of common stock subject to the RSUs were vested when granted or vest within one year of grant, and issuance of shares thereunder is deferred to the date the holder is no longer providing service to RiceBran Technologies.
[2] We reversed $0.2 million of expense recognized in prior periods on forfeited RSU shares in the amounts indicated in the unrecognized stock compensation column.
[3] Represents shares of common stock subject to RSUs which were vested when granted.
[4] A total of 227,062 shares of common stock subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Subject to a minimum service period, as described in the next sentence, the RSU shares vest as to (i) 22,706 shares on the date the vesting price equals or exceeds $5.00 per share, (ii) 68,119 shares on the date the vesting price equals or exceeds $10.00 per share and (iii) 136,237 shares on the date the vesting price equals or exceeds $15.00 per share. Vesting on the RSU shares occurs the later of the one-year anniversary of the grant and the date the shares reach the vesting price indicated in the preceding sentence. The RSUs expire on the fifth anniversary of each grant at dates ranging through August 2024.
[5] RSUs for a total of 450,400 shares of common stock vest in June 2021 and issuance of shares of common stock subject to each of those RSUs is deferred to the date the holder is no longer providing service to RiceBran Technologies.
[6] We expensed $0.1 million related to recognition of the unrecognized compensation associated with the cancelled RSU shares in the three months ended March 31, 2020.
v3.20.2
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrants Activity (Details) - Warrants [Member] - $ / shares
 3 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Shares Under Warrants [Roll Forward]        
Outstanding at beginning of period (in shares) 6,645,916 7,267,280 7,532,280  
Cash exercised (in shares)   (12,948)    
Cashless exercised (in shares) [1]   (215,740)    
Expired (in shares)   (392,676) (265,000)  
Outstanding at end of period (in shares) 6,645,916 [2] 6,645,916 7,267,280 7,532,280
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]        
Outstanding at beginning of period (in dollars per share) $ 0.98 $ 1.18 $ 1.32  
Cash exercised (in dollars per share)   0.96    
Cashless exercised (in dollars per share) [1]   0.96    
Expired (in dollars per share)   4.60 5.25  
Outstanding at end of period (in dollars per share) $ 0.98 [2] $ 0.98 $ 1.18 $ 1.32
Warrants, Additional Disclosures [Abstract]        
Outstanding, weighted average remaining contractual life 1 year 4 months 24 days [2] 1 year 8 months 12 days 1 year 8 months 12 days 1 year 10 months 24 days
Issuance of common stock upon cashless exercise of warrants (in shares)   54,629    
Warrants under cashless exercise feature (in shares) 6,645,916 6,645,916 7,267,280 7,532,280
Weighted average exercise price (in dollars per share) $ 0.98 $ 1.18 $ 1.18 $ 1.32
$0.96 [Member]        
Shares Under Warrants [Roll Forward]        
Outstanding at end of period (in shares) 3,484,675      
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]        
Outstanding at end of period (in dollars per share) $ 0.96      
Warrants, Additional Disclosures [Abstract]        
Warrants under cashless exercise feature (in shares) 3,484,675      
Weighted average exercise price (in dollars per share) $ 0.96      
$5.25 [Member]        
Shares Under Warrants [Roll Forward]        
Outstanding at end of period (in shares) 25,000      
Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]        
Outstanding at end of period (in dollars per share) $ 5.25      
Warrants, Additional Disclosures [Abstract]        
Warrants under cashless exercise feature (in shares) 25,000      
Weighted average exercise price (in dollars per share) $ 5.25      
[1] In the three months ended June 30, 2020, we issued 54,629 shares of common stock upon the cashless exercise of the warrants.
[2] Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. As of September 30, 2020, warrant holders may elect to exercise cashless warrants for 3,484,675 shares of common stock at an exercise price of $0.96 per share and 25,000 shares of common stock at an exercise price of $5.25 per share. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. If we fail to maintain a registration statement for the resale of shares under certain other warrants, the shares under those warrants may again become exercisable using a cashless exercise feature
v3.20.2
INVOLUNTARY CONVERSION OF ASSETS (Details) - Hurricane Damage [Member]
$ in Millions
 3 Months Ended
Sep. 30, 2020
USD ($)
Unusual or Infrequent Item, or Both [Line Items]  
Costs related to hurricane damage $ 0.1
Charges deductible under insurance policy 0.1
Insurance settlement advance proceeds 0.3
Insurance settlement accrued receivable 0.7
Net loss in involuntary conversion of assets 0.1
Building, Machinery and Equipment [Member]  
Unusual or Infrequent Item, or Both [Line Items]  
Write down of assets $ 0.9
v3.20.2
LOSS PER SHARE (EPS) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
NUMERATOR [Abstract]        
Basic and diluted - loss from continuing operations $ (2,774) $ (3,326) $ (9,756) $ (9,996)
DENOMINATOR [Abstract]        
Weighted average number of shares of shares of common stock outstanding (in shares) 40,691,824 33,057,010 40,232,289 31,947,087
Weighted average number of shares of common stock underlying vested restricted stock units (in shares) 132,457 0 47,577 0
Basic EPS - weighted average number of shares outstanding (in shares) 40,824,281 33,057,010 40,279,866 31,947,087
Effect of dilutive securities outstanding (in shares) 0 0 0 0
Diluted EPS - weighted average number of shares outstanding (in shares) 40,824,281 33,057,010 40,279,866 31,947,087
v3.20.2
FAIR VALUE MEASUREMENTS (Details)
$ in Millions
Sep. 30, 2020
USD ($)
Level 3 [Member]  
Fair Value Measurements [Abstract]  
Fair value of operating leases liabilities $ 0.2
v3.20.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Legal Matters [Abstract]        
Cost of goods sold $ 5,955 $ 5,659 $ 21,817 $ 18,143
Legal Matters [Member]        
Legal Matters [Abstract]        
Cost of goods sold $ 500   $ 700  
v3.20.2
RELATED PARTY TRANSACTIONS (Details)
 3 Months Ended 9 Months Ended
Mar. 31, 2019
$ / shares
shares
Sep. 30, 2020
Nominee
$ / shares
Minimum [Member]    
Related Party Transaction Information [Abstract]    
Ownership percentage   19.99%
Ari Gendason [Member] | Continental Grain Company [Member]    
Related Party Transaction Information [Abstract]    
Ownership interest percentage   25.40%
Sale of common stock (in shares) | shares 666,667  
Share price (in dollars per share) $ 3.00  
Exercise price per warrant (in dollars per share)   $ 0.01
Number of nominee for the Board of Directors related party can designate | Nominee   1
Ari Gendason [Member] | Continental Grain Company [Member] | Private Placement [Member]    
Related Party Transaction Information [Abstract]    
Shares callable by Prefunded Warrant (in shares) | shares 1,003,344  
Share price (in dollars per share) $ 2.99  
v3.20.2
TRANSACTIONS WITH EMPLOYEES (Details) - Wayne Wilkison [Member] - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Sep. 30, 2020
Dec. 31, 2019
Employee Transaction [Abstract]      
Amount paid to related parties $ 1.4    
Amounts payable to entities   $ 0.0 $ 0.0